

UNIVERSITÀ DEGLI STUDI DI MILANO

Procedura di selezione per la chiamata a professore di I fascia da ricoprire ai sensi dell'art. 18, comma 1, della Legge n. 240/2010 per il settore concorsuale 06/D3 - MALATTIE DEL SANGUE, ONCOLOGIA E REUMATOLOGIA, (settore scientifico-disciplinare MED/16 - REUMATOLOGIA) presso il Dipartimento di Scienze Biomediche e Cliniche L. Sacco, (avviso bando pubblicato sulla G.U. 94 del 01/12/2020) - Codice concorso 4493

**[Piercarlo Sarzi Puttini]
CURRICULUM VITAE**

INFORMAZIONI PERSONALI (NON INSERIRE INDIRIZZO PRIVATO E TELEFONO FISSO O CELLULARE)

COGNOME	SARZI PUTTINI
NOME	PIERCARLO
DATA DI NASCITA	19 NOVEMBRE 1955

**INSERIRE IL PROPRIO CURRICULUM
(non eccedente le 30 pagine)**

PIERCARLO SARZI PUTTINI, MD
Direttore UOC di Reumatologia
ASST Fatebenefratelli-Sacco, Polo Universitario "L. Sacco"

Professore straordinario Reumatologia
c/o Dip. di Scienze Biomediche e Cliniche "L. Sacco"
Via G.B. Grassi, 74
20157 Milano, Italia

Lingue:

Inglese (conoscenza ottima)

QUALIFICHE

- Abilitazione Scientifica Nazionale 06/D3 – I Fascia dal 03/12/2013
- Professore Straordinario dal 2017 di Reumatologia presso l'Università Statale di Milano
- Direttore dal 2007 di Unità Operativa Complessa di Reumatologia (dotati di 10 posto-letto e di outpatient clinic) presso l'ASST Fatebenefratelli-Sacco di Milano
- Titolare dell'Insegnamento di "Reumatologia" del corso integrato "Specialità Mediche e Chirurgiche IV" presso la Facoltà di Medicina della medesima Università
- Docente presso il corso di Laurea in Podologia Dip. Scienze Biomediche, Chirurgiche ed Odontoiatriche Università degli Studi di Milano Istituto Ortopedico "R. Galeazzi" (responsabile del corso di malattie dismetaboliche e infiammatorie)
- Docente presso la Scuola di Specializzazione in Reumatologia, sede Amministrativa Università di Milano.

Titoli di studio

1974 - Maturità Classica conseguita presso il Liceo Classico "Virgilio" di Mantova
1981 - Laurea in Medicina e Chirurgia presso l'Università degli studi di Parma
1985 - Specializzazione in Reumatologia, Università di Milano
1989 - Specializzazione in Terapia Fisica e Riabilitazione, Università di Milano
1994 - Specializzazione in Medicina Interna, Università di Pavia

Curriculum formativo professionale

Ho conseguito la Maturità classica presso il Liceo Classico "Virgilio" di Mantova nel 1974. Nell'anno scolastico 1972-1973 sono risultato vincitore di una borsa di studio offerta dall' AFS (American Field Service), un'associazione internazionale che si occupa di scambi culturali, soggiornando per 1 anno presso una famiglia americana a Hingham (Boston - Mass) e frequentando l'ultimo anno della scuola superiore americana.

Iscritto nel 1974 alla Facoltà di Medicina e Chirurgia presso l'Università degli Studi di Parma, ove mi sono laureato il 26-11-1981 con una tesi di argomento reumatologico: "*Glicoproteine alfabetica in corso di artrite reumatoide*" (relatore Prof. U. Ambanelli).

Nell'anno accademico 1981-1982 mi sono iscritto alla Scuola di Specializzazione in Reumatologia presso l'Università di Studi di Milano, ove mi sono specializzato nel 1985 con la seguente tesi: "*Sindrome fibromialgica primaria*" (relatore Prof. B. Colombo).

Nel periodo gennaio-giugno 1982 ho frequentato l'Unità di Reumatologia presso il Dipartimento di Medicina dell'Università di Washington, Seattle, USA (sotto la guida del Prof. P. Simkin).

Nel periodo 03/01/83 - 03/07/83 ho effettuato tirocinio pratico ospedaliero presso il servizio di Reumatologia dell'Ospedale L. Sacco di Milano (dirigente prof. I. Caruso), riportando il giudizio finale di ottimo. Nell'anno accademico 1986-1987 mi sono iscritto alla Scuola di specializzazione in Terapia Fisica e Riabilitazione presso l'Università di Milano, ove mi sono specializzato nel 1989. Nell'anno accademico 1990-1991 mi sono iscritto alla Scuola di Specializzazione di Medicina Internapresso l'Università di Pavia, ove mi sono specializzato nel 1995.

Corsi di formazione e master

1982	Post-doc Fellowship in Rheumatology Unit, Department of Medicine, University of Washington Seattle, USA. (Supervision: Prof. P. Simkin)
1994	2nd EULAR postgraduate Course Rheumatology (Marsiglia, 7-13/09/1994)
1996	3rd EULAR postgraduate Course In Rheumatology (Oxford, 11- 15/09/1996)
1996	EULAR Course on the Scientific Basis of Rheumatology (Oxford, 7-10/09/1996)
1997	4th EULAR posrgraduate Course in Rheumatology (Praha, 8-14/ 1997)
2001	Corso Nazionale di Formazione in Reumatologia: Cost, Efficacy in Rheumatology, 8-10/02/01 e 22-24/03/01 – University of Ancona, Italy
2015	Master di II livello terapia del dolore – Università degli Studi di Parma

Corsi di economia gestionale:

1998	Manager Course: “Principi di organizzazione, leadership, principi di gestione delle risorse economiche nel SSN” (presso l’IREF, durata otto giorni, Gennaio/ Febbraio 1998)
1998	Course for Medical Manager “IPPOCRATE” (presso la SDA Bocconi nel Febbraio/Marzo 1998)
2005	Manager Course (Scuola di direzione in Sanità, Regione Lombardia)

Società Scientifiche

- Società Italiana di Reumatologia (SIR)
- Collegio Medici Ospedalieri Italiani (CREI)
- ACR (American College of Rheumatology)
- Myopain Society
- European Scleroderma Trials and Research group (EUSTAR)
- European League Against Rheumatism (EULAR)
- European Network of Fibromyalgia Associations

ATTIVITA' CLINICO-ASSISTENZIALE

Dal 01/01/84 - 24/10/84 ho frequentato il Servizio di Reumatologia dell'Ospedale “L. Sacco” in qualità di medico borsista

1985-1986	Assistente medico di Reumatologia incaricato a tempo definito
1986-1987	Assistente medico di Reumatologia di ruolo a tempo definito
1987-1994	Assistente medico di Reumatologia di ruolo a tempo pieno
1994-1996	Aiuto corresponsabile di Reumatologia a tempo indeterminato
1996-2007	Dirigente medico di 1° livello di Reumatologia a tempo pieno

01-05-2007 a tutt'oggi

Direttore Unità Operativa Complessa di Reumatologia ASST Fatebenefratelli-Sacco - Milano

Tipologia qualitativa e quantitativa delle prestazioni effettuate

L'Unità Operativa Complessa di Reumatologia dell'ASST Fatebenefratelli-Sacco di Milano gestisce 9 posti letto di degenza ordinaria + 2 letti di DH dedicati alle malattie reumatiche; sono inoltre aperti 8 ambulatori per la gestione del paziente reumatico.

L'attività assistenziale svolta in questi anni dall'Unità Operativa Complessa di Reumatologia ha riguardato i pazienti ricoverati, lo sviluppo di attività di outpatient e di ambulatori dedicati.

L'Unità Operativa Complessa di Reumatologia è dotata di 3 apparecchi per ecografia muscoloscheletrica e di 2 capillaroscopi. L'organico attuale dell'UOC di Reumatologia consta di 7 medici strutturati, 1 specialista in Reumatologia a contratto determinato, 1 biologo ricercatore a tempo determinato e 2 amministrativi.

Ruolo nella comunità reumatologica

Dal 2019 ad oggi è membro del Consiglio Direttivo del Collegio dei Reumatologi Ospedalieri Italiani (CREI) con la qualifica di responsabile scientifico.

Dal 2008 al 2012 e dal 2015 al 2018 ha fatto parte del **Consiglio Direttivo della Società Italiana di Reumatologia (SIR)**; ricoprendo la carica di segretario generale dal 2010 al 2012; dal 2015 è responsabile del gruppo di studio sul dolore in reumatologia. E' membro Internazionale dell'American College of Rheumatology (ACR)-

Da 5 anni gestisce un corso residenziale annualmente per gli specializzandi iscritti al 3° anno della scuole di specialità in reumatologia sul dolore cronico in reumatologia sotto l'egida della Società Italiana di Reumatologia

Ruolo nelle associazioni dei pazienti

Presidente dell'Associazione Italiana Sindrome Fibromialgica, che è stata costituita il 30 Novembre 2005 ed è divenuta ufficialmente Onlus il 12 Dicembre 2005, poi ODV nel 2020.

Le attività istituzionali svolte dall'Associazione sono il Congresso Nazionale AISF, l'Assemblea della Redazione del notiziario semestrale dell'Associazione Italiana Sindrome Fibromialgica AISF ODV "Il Caleidoscopio" e pubblicazione con aggiornamenti periodici del "Manuale del paziente fibromialgico".

Coordinamento della Sede Nazionale e delle 25 Sezioni (Attività di ascolto telefonico e risposte via e-mail ai pazienti, Soci e non Soci, dando loro assistenza e consigli con le relative attività segretariali, amministrative-contabili).

ATTIVITA' DIDATTICA

- dal 1988 al 1991: Insegnamento negli aa. 88/89, 89/90, 90/91 presso la Scuola Infermieri Professionali Ospedale L. Sacco
- dal 1994 al 1997: Collaborazione all'attività didattica nel corso integrato di Malattie del Sistema Immunitario e Reumatologia negli aa. 94/95, 95/96, 96/97
- dal 1995: Attività di docenza (ore 16) nel corso di formazione specifica in Medicina Generale
- dal 1997 al 2000: Corso di insegnamento di Reumatologia (ore 4) nel corso di Diploma Universitario per Infermiere (aa. 97/98, 98/99, 99/00)
- dal 2001 al 2015: Professore a contratto di Reumatologia Università degli studi di Milano c/o Dipartimento di Scienze Biomediche e Cliniche "L. Sacco" con i seguenti incarichi:
 - dal 2001 al 2002 - Cdl in Medicina e Chirurgia Semeiotica e sistematica II
 - dal 2002 al 2003 - Cdl in Medicina e Chirurgia semeiotica e diagnostica reumatologica
 - dal 2003 al 2004 - Cdl in Medicina e Chirurgia Semeiotica e sistematica II
 - dal 2004 al 2005 - Cdl specialistica in Medicina e Chirurgia Semeiotica reumatologica semeiotica e sistematica II
 - dal 2005 al 2006 - Cdl specialistica in Medicina e Chirurgia Semeiotica reumatologica semeiotica e sistematica II

- dal 2006 al 2007 - Cdl a ciclo unico in Medicina e Chirurgia - Semeiotica reumatologica - semeiotica e sistematica II
- dal 2007 al 2008 - Sds in Medicina Interna I - Semeiotica reumatologica
- dal 2007 al 2008 - Sds in Reumatologia Fisiopatologia apparato locomotore
- dal 2008 al 2009 - Sds in Reumatologia Sindrome fibromialgica
- dal 2009 al 2010 - Sds in Reumatologia Sindrome fibromialgica III anno
- dal 2010 al 2011 - Cdl in Medicina e Chirurgia Semeiotica e patologia degli apparati II
- dal 2010 al 2011 - Sds in Reumatologia Clinica Reumatologia 3
- dal 2011 al 2015 - Sds in Reumatologia - Clinica Reumatologia 3

-dal 2016 al 2018: Professore Straordinario di Reumatologia Università degli Studi di Milano c/o Dipartimento di Scienze Biomediche e Cliniche "L. Sacco" con i seguenti incarichi:

- dal 2016 al 2018 - Sds in Reumatologia Clinica Reumatologia 3
- dal 2016 al 2018 - Cdl in Medicina e Chirurgia Semeiotica e patologia degli apparati II

- dal 2019 Professore straordinario di Reumatologia Università degli Studi di Milano c/o Dipartimento di Scienze Biomediche e Cliniche "L. Sacco" con i seguenti incarichi:

- dal 2019 - Sds in Reumatologia Clinica Reumatologia 3
- dal 2019 - Cdl in Medicina e Chirurgia Semeiotica e patologia degli apparati II

Cdl = corso di laurea; Sds = scuola di specializzazione

-Dal 2019 titolare del corso di insegnamento di responsabile del corso di malattie dismetaboliche e infiammatorie) presso il corso di laurea triennale in podologia, Università degli studi Milano, sede Istituto Ortopedico Galeazzi, Milano

Attività di Tutor

- Tutor per studenti del Corso Di Laurea Magistrale in Medicina e Chirurgia, Corso di Laurea in Podologia, Scuola di Specialità in Reumatologia
- presso la Facoltà di Medicina e Chirurgia dell'Università Statale di Milano attività di Tutor e Relatore di Tesi di 10 studenti del Corso di Laurea Magistrale in Medicina e Chirurgia, 2 studenti del Corso di Podologia, 6 specializzandi della Scuola di Specializzazione in Reumatologia e 3 iscritti al Dottorato di Ricerca in Reumatologia Sperimentale presso l'Università degli studi di Padova.

Organizzazione di Convegni a carattere Internazionale

Organizzazione dei seguenti Congressi Internazionali (come presidente o co-presidente o nel board organizzativo):

- International conference on "Heart, Rheumatism and autoimmunity". Milan, February 5-7, 2004.
- 2nd International Conference on "Heart, Rheumatism and autoimmunity". Pescara, May 19-20, 2005.
- Skin Rheumatism and Autoimmunity. Abano Terme (Padova) 2-4 February 2006
- 5th International Congress on Autoimmunity, Sorrento, Italy, 8-12 November, 2006
- Infections, Rheumatism and Autoimmunity. Milan (Italy) 6-8 March 2008
- Controversies in Rheumatology and Autoimmunity. Florence (Italy) 10-12 March, 2011
- Controversies in Rheumatology and Autoimmunity. Budapest (Hungary) 4-6 April, 2013
- Controversies in Rheumatology and Autoimmunity. Sorrento (Italy) 12-14 March, 2015
- 10th European Meeting on Systemic lupus erythematosus. Venice (Italy) 5-8 Ottobre 2016
- International Congress on Controversies on Fibromyalgia, Vienna (Austria) , 4-5 Marzo 2019
- 2nd International Congress on Controversies on Fibromyalgia, on line, 9-10 Novembre 2020
- DISH, Spondyloarthritis and osteoarthritis: Similarities and differences, 9 Dicembre 2020

ATTIVITA' SCIENTIFICA

Principali linee di ricerca

Studio di coorte di pazienti con artrite reumatoide o spondiloartriti.

Identificazione e follow-up di pazienti con artrite reumatoide e spondiloartriti con l'obiettivo di definire alcuni aspetti clinici e l'evoluzione della malattia, in particolare: a) incidenza di remissioni, riacutizzazioni, complicanze; b) sviluppo di danno permanente; c) valutazione della qualità di vita e stili di coping; d) fattori prognostici; e) sopravvivenza; f) cause di morte. La struttura da me diretta fa parte dei registri LOHREN e GISEA

Studio su sindrome fibromialgica e dolore cronico in reumatologia

Identificazione e follow-up di pazienti affetti da sindrome fibromialgica con pubblicazione di numerosi articoli scientifici. Membro del board internazionale che ha prodotto le raccomandazioni EULAR per il trattamento della sindrome fibromialgica e membro del board dell' American Pain Society che ha prodotto i più recenti criteri per la diagnosi di sindrome fibromialgica

Comorbidità e malattie reumatiche

Autore e coautore di numerosi lavori sulle comorbidità nelle malattie reumatiche, in particolare rischio cardiovascolare e infettivologico

Lupus eritematoso sistemico e malattie autoimmuni

Autore e coautore di numerose pubblicazioni sul LES e su malattie autoimmuni, membro effettivo di EUSTAR

Diagnosi e trattamento precoce delle malattie reumatiche

Principal investigator in numerosi studi sul trattamento delle patologie reumatiche ed autoimmuni

PRINCIPAL INVESTIGATOR per i seguenti Studi Clinici internazionali (www.clinicaltrials.gov)

(Fase II, III, IV), che si sono svolte e si stanno svolgendo presso l'Unità Operativa Complessa di Reumatologia dell'ASST Fatebenefratelli-Sacco

- Studio PH-F8IL10-03/12 – Promotore Philogen S.p.A
- CC-10004-PSA-005 e CC-10004-PSA-003 - PALACE 2 – Promotore Celgene S.r.l.
- ML25728, ML28699 e MK-8259 – Promotore Merck Sharp & Dohme S.p.A
- STUDY RA0069 e STUDY RA0055 - Promotore UCB Pharma S.p.A
- JADZ, JADX, JADY - Promotore Eli Lilly S.p.A
- THE Ra BIODAM STUDY - Promotore CARE ARTHRITIS
- CAIN 457F2320 e STUDIO CAIN 457F3301 - Promotore Novartis Farma S.p.A
- STUDIO D3461C00005 - Promotore Astra Zeneca S.p.A
- STUDY GP17-302 – Promotore Sandoz, Hexal AG
- STUDIO CNT01275PSA4003 – Promotore Janssen-Cilag International NV
- STUDY RHBW: A Study of Ixekizumab (LY2439821) - Promotore Eli Lilly S.p.A
- STUDIO M13-545 – STUDIO M14-465 Promotore AbbVie S.r.l.
- STUDIO CAIN 457F3301 - Promotore Novartis Farma S.p.A
- Studio CHRONOS - Promotore Novartis Farma S.p.A
- Studio SABLE – Promotore GlaxoSmithKline S.p.A
- Studio PA0010 e Studio PA0011 – Promotore UCB Pharma S.p.A

Co-editor della rivista in lingua Inglese /italiano "Reumatismo" e della rivista "Beyond Rheumatology"; editor del supplemento annuale su clinical and experimental rheumatology su "Fibromyalgia and related syndromes".membro della

commissione editoriale delle rivista "Autoimmunity Reviews" e di altre riviste scientifiche. Sono socio di varie società scientifiche italiane ed estere (SIR, CREI, American College of Rheumatology, Myopain Society).

Nel corso degli ultimi 15 anni ho partecipato in qualità di responsabile scientifico, relatore o di auditore a numerosi congressi nazionali ed internazionali.

Nel luglio 2017 la UOC di Reumatologia da me diretta ha vinto il Bando SIR (Società Italiana di Reumatologia) per il conferimento di un incarico a tempo determinato, per un Dirigente Medico – Disciplina Reumatologia, Area Medica e delle Specialità Mediche della durata di n. 3 Anni, ai sensi dell'Art. ex. 15 Septis.

Reviewer per le seguenti riviste scientifiche:

Annals of Rheumatic Diseases, Arthritis Research and Therapy, Arthritis and Rheumatism, Arthritis Care and Research, Autoimmunity Reviews, Journal of Autoimmunity, Clinical Experimental Rheumatology, Lupus, Nature Clinical Practice Rheumatology, Reumatismo, Rheumatology, Scandinavian Journal of Rheumatology, The Journal of Rheumatology.

ATTIVITA' EDITORIALE

LIBRI

- Fabiola Atzeni, Marcello Govoni, Fausto Salaffi, **Piercarlo Sarzi Puttini** Collana: quaderni di clinimetria - semeiotica reumatologia - parte iii - bacino, anca, arto inferiore e piede - - Mattioli 1885 - fidenza 2015
- Fabiola Atzeni, Marcello Govoni, Fausto Salaffi, **Piercarlo Sarzi Puttini** Collana: quaderni di clinimetria - semeiotica reumatologia parte ii - colonna vertebrale e articolazione temporo mandibolare - - Mattioli 1885 - fidenza 2015
- Fabiola Atzeni, Marcello Govoni, Fausto Salaffi, **Piercarlo Sarzi Puttini** Collana: quaderni di clinimetria - semeiotica reumatologia - parte i - arto superiore - - Mattioli 1885 - fidenza 2014
- **Piercarlo Sarzi-Puttini**, Fabiola Atzeni, Marco Cazzola manuale pratico per il paziente affetto da sindrome fibromialgia - Aessegi srl - milano - giugno 2014
- Fabiola Atzeni, Marcello Govoni, Fausto Salaffi, **Piercarlo Sarzi Puttini** Collana: quaderni di clinimetria - parte i - arto superiore - - Mattioli 1885 - fidenza 2014
- Salaffi Fausto; **Piercarlo Sarzi Puttini**; Cimmino Marco Amedeo; Cazzola Marco; Ciapetti Alessandro; Atzeni Fabiola Collana: quaderni di clinimetria - dolore cronico muscoloscheletrico. inquadramento clinico e scale di valutazione - Mattioli 1885 - fidenza 2012
- Fabiola Atzeni, Marco Cazzola, **Piercarlo Sarzi Puttini**, Stefano Stisi - fibromialgia - Mattioli 1885 - fidenza 2010
- **Piercarlo Sarzi-Puttini**, Marco Cazzola il manuale del paziente affetto da sindrome fibromialgica - gestione integrata tra personale sanitario e paziente - - gpa.net srl - milano – 2009
- Editors **Piercarlo Sarzi Puttini**, A. Doria, G. Girolomoni, A. Kuhn The skin in Systemic Autoimmune Diseases.. Ed Elsevier 2006
- M. Cazzola, **Piercarlo Sarzi Puttini** La Riabilitazione del paziente affetto da artrite reumatoide. Casa Editrice Mattioli, 2004
- M. Carrabba, **Piercarlo Sarzi Puttini** Arthritis in the Elderly: new perspectives in diagnosis and management., Casa Editrice Mattioli, 2003
- **Piercarlo Sarzi Puttini**, M. Cazzola La sindrome fibromialgica.. Edi-Ermes 2001
- M. Carrabba, **Piercarlo Sarzi Puttini** New Trends In Osteoarthritis., Casa Editrice Mattioli, 2001
- **Piercarlo Sarzi Puttini**, M Cazzola La sindrome fibromialgica primaria., ESAMfuture 1991

CAPITOLI DI LIBRI

- Fabiola Atzeni, Ignazio Francesco Masala, **Piercarlo Sarzi-Puttini**. **Clinical features of fibromyalgia syndrome**. Chapter 6. Fibromyalgia Syndrome and Widespread Pain. Ed. Hauser F. and Perrot S. Wolters Kluwer 2018.
- Fabiola Atzeni, Rossella Talotta, **Piercarlo Sarzi-Puttini**. **Fibromyalgia and autoimmunity**. Chapter 24. Fibromyalgia Syndrome and Widespread Pain. Ed. Hauser F. and Perrot S. Wolters Kluwer 2018.
- Fabiola Atzeni, Francesco Caso, Luisa Costa, **Piercarlo Sarzi-Puttini**, Ignazio F. Masala - Chapter 7. **Conventional and Biological DMARDs in Systemic Rheumatic Diseases: Perioperative Risk/Benefit Management**. Handbook of Systemic Autoimmune Diseases, Volume 15, 2018, Pages 161-182 - - AMSTERDAM 2018
- F. Atzeni, F. Caso, I. F. Masala, **Piercarlo Sarzi-Puttini** Chapter 16: Cardiovascular Involvement in Psoriatic Arthritis - Handbook of Systemic Autoimmune Diseases, Volume 14, 2017, Pages 409-426 - AMSTERDAM 2017
- M. Turiel, L. Gianturco, F. Atzeni, **Piercarlo Sarzi-Puttini**, M. Corda - Chapter 8: Cardiac Imaging Techniques in Systemic Autoimmune Diseases - Handbook of Systemic Autoimmune Diseases, Volume 14, 2017, Pages 183-207 AMSTERDAM 2017
- F. Atzeni, R. Talotta, I. F. Masala, **Piercarlo Sarzi-Puttini** Chapter 19: **Spondyloarthritis and Gastrointestinal Involvement** - Handbook of Systemic Autoimmune Diseases, Volume 13, 2017, Pages 349-361 - AMSTERDAM 2017
- Fabiola Atzeni, **Piercarlo Sarzi-Puttini**. **Tumor Necrosis Factor**. Brenner's Encyclopedia of Genetics, 2nd Edition 2016 update.
- Fabiola Atzeni, **Piercarlo Sarzi-Puttini**. **Tumor Necrosis Factor**. Brenner's Encyclopedia of Genetics, 2nd Edition 2012
- **Piercarlo Sarzi-Puttini**, Fabiola Atzeni, Giannantonio Cassisi, Marco Cazzola **Fibromialgia e Reumatismi extra-articolari** Capitolo 173. Trattato di Medicina Interna Ed. Gasbarrini, 2011.
- Fabiola Atzeni, **Piercarlo Sarzi-Puttini**. Autoimmunity and the newer biopharmaceuticals *Autoantibodies (Second Edition)*, 2007, Pages 783-791
- Fabiola Atzeni, **Piercarlo Sarzi-Puttini**, Maurizio Cutolo, Rainer H. Straub Chapter 27 **Modulation of Hormone Axes by Anti-TNF Therapy**. Handbook of Systemic Autoimmune Diseases, 2008, 9, 301-308
- **Piercarlo Sarzi-Puttini**, Fabiola Atzeni, Mario Carrabba. Rheumatoid arthritis and skin. *Handbook of Systemic Autoimmune Diseases*, Chapter 13 Volume 5, 2006, Pages 161-183. **Rheumatoid Arthritis and the Skin**.
- **P. Sarzi-Puttini**; Cazzola Marco; Atzeni Fabiola. **Artrite reumatoide: dall'inquadramento clinico al progetto riabilitativo**. 2010 Editore MATTIOLI 1885
- **Sarzi-Puttini Piercarlo**; Cazzola Marco; Atzeni Fabiola; Stisi Stefano **Fibromialgia 2008**
- **P. Sarzi-Puttini**, F. Atzeni. **Sindrome Fibromialgica**. In: **Malattie Reumatologiche e osteometaboliche**. Mattioli Editore, 2007
- **P. Sarzi-Puttini**, F. Atzeni. **La sindrome fibromialgica**. **Riabilitazione reumatologica approccio multidisciplinare**. Ed. S. Maddali Bongi. *Capitolo 23.a* pp. 979-94.
- **P. Sarzi-Puttini**, F. Atzeni. **Il trattamento del malato affetto da sindrome fibromialgica**. **Riabilitazione reumatologica approccio multidisciplinare**. Ed. S. Maddali Bongi. *Capitolo 23.b*. pp.995-1018.
- **P. Sarzi-Puttini**, Atzeni. F **FANS topici; indicazioni cliniche e tollerabilità gastroenterica**. **La gastropatia da FANS**. **Imaging in gastroenterologia**. Ed *libreria Cortina Verona*; Ed *G Bianchi Porro, M Lazzaroni, G Maconi 2004*;; pp 81-93 Editore MATTIOLI 1885

- Carrabba M., **Sarzi-Puttini P.** Arthritis in the elderly: New perspectives in diagnosis and treatment. Ed. Mattioli 1885, 2003, pp 1-283 28. P Sarzi-Puttini, F Atzeni, M Carrabba. Osteoarthritis of the spine. In: New Trends in Osteoarthritis, Eds M Carrabba, P Sarzi-Puttini, 2002; pp 88-97
- Carrabba M, **Sarzi-Puttini P.** New trends in Osteoarthritis. Ed Mattioli 1885, 2002, pp 1-158.
- Sarzi-Puttini P, Cazzola M: La sindrome fibromialgica. Edi-Ermes Milano Editore 2001; pp 1-229
- Cazzola M, **Sarzi-Puttini P.** La sindrome fibromialgica.eziopatogenesi e sintomatologia. In: Il dolore vertebrale .Ed V Rucco. Verduci Editore, 1999; pp 111-121. 32.
- **Sarzi-Puttini P.**,Cazzola M,. La sindrome fibromialgica. Problemi terapeutici. In: Il dolore vertebrale .Ed V Rucco. Verduci Editore, 1999; pp 122-127
- **Sarzi-Puttini P**, Cazzola M.: La sindrome fibromialgica primaria. ESAM Editore, Roma, 1991
- Caruso I, **Sarzi-Puttini P.**: Malattie reumatiche e autoimmunità. In: Manuuale di Patologia Medica -Masson Editore 2a Edizione 1987; pp 143-170
- **Sarzi-Puttini P.**: Criteri di scelta dei FANS nelle malattie reumatiche. Medico e paziente 1985; pp16-30; 10
- Cazzola M, Bombaci A, **Sarzi-Puttini P.**: La Crioterapia in medicina riabilitativa. Eur Med Phis 1994; 30: 177-191
- **Sarzi-Puttini P.** La sindrome fibromialgica primaria. Atti del Corso di patologia, Milano 1994; pp. 49-65
- **Sarzi-Puttini P.** Anticorpi antinucleo, anti-DNA e anti-ENA. Atti corso "significato clinico e diagnostico dei tests di laboratorio nelle malattie reumatiche. Milano 5-6 maggio 1994, Accademia Nazionale di Medicina.
- Comi D, **Sarzi-Puttini P**, Brugnani M, Gianino A, Montrone F, Caruso I.: Possibili strategie nutrizionali dell'artrite reumatoide. In: " Aggiornamenti in nutrizione clinica" pp263-265, 1993
- Caruso I, **Sarzi-Puttini P**, Cazzola M, Azzolini V.: Studio in doppio cieco 5-idrossi-L-triptofano (5-HTP) versus placebo nel trattamento della sindrome fibromialgica primaria. In: "La serotonina" - Ed. Borromei A, Gaggi R. 1989; pp 34-48
- Caruso I, **Sarzi-Puttini P**, Cazzola M, Azzolini V. La sindrome fibromialgica primaria. In: "La serotonina"- Ed. Borromei A, Gaggi R. 1989; pp 29-38

Parametri su Scopus

Number of papers included 544; Cited 14719 in 11687 documents ; h-index 63

Pubblicazioni scientifiche (riviste internazionali con impact factor)

Atzeni F, Sciortino D, Nucera V, Fries W, **Sarzi-Puttini P**, Salaffi F, Galloway J, Bonitta G. Study of entheses in patients with spondyloarthritis and inflammatory bowel disease with and without fibromyalgia: The importance of ultrasonography. Joint Bone Spine. 2020 Oct;87(5):507-508. doi: 10.1016/j.jbspin.2020.04.001. Epub 2020 Apr 25.

Sarzi-Puttini P, Marotto D, Antivalle M, Salaffi F, Atzeni F, Maconi G, Monteleone G, Rizzardini G, Antinori S, Galli M, Ardizzone S. How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion. Autoimmun Rev. 2020 Jul;19(7):102574. doi: 10.1016/j.autrev.2020.102574. Epub 2020 May 5. (**Q1, IF 7.71**)

Antinori S, Bonazzetti C, Gubertini G, Capetti A, Pagani C, Morena V, Rimoldi S, Galimberti L, **Sarzi-Puttini P**, Ridolfo AL. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia? Autoimmun Rev. 2020 Jul;19(7):102564. doi: 10.1016/j.autrev.2020.102564. Epub 2020 May 5

Monteleone G, **Sarzi-Puttini PC**, Ardizzone S. Preventing COVID-19-induced pneumonia with anticytokine therapy. Lancet Rheumatol. 2020 May;2(5):e255-e256. doi: 10.1016/S2665-9913(20)30092-8. Epub 2020 Apr 6

- Marotto D, **Sarzi-Puttini P**. What is the role of rheumatologists in the era of COVID-19? *Autoimmun Rev*. 2020 Jun;19(6):102539. doi: 10.1016/j.autrev.2020.102539. Epub 2020 Apr 3
- Salaffi F, Di Carlo M, Farah S, Atzeni F, Buskila D, Ablin JN, Häuser W, **Sarzi-Puttini P**. Diagnosis of fibromyalgia: comparison of the 2011/2016 ACR and AAPT criteria and validation of the modified Fibromyalgia Assessment Status. *Rheumatology (Oxford)*. 2020 Oct 1;59(10):3042-3049. doi: 10.1093/rheumatology/keaa061. **(Q1, IF 5.60)**
- Sarzi-Puttini P**, Giorgi V, Sirotti S, Marotto D, Ardizzone S, Rizzardini G, Antinori S, Galli M. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? *Clin Exp Rheumatol*. 2020 Mar-Apr;38(2):337-342. Epub 2020 Mar 22
- Bodio C, Grossi C, Pregnolato F, Favalli EG, Biggioggero M, Marchesoni A, Murgo A, Filippini M, Migliorini P, Caporali R, Pellerito R, Ciccia F, **Sarzi-Puttini P**, Perosa F, Paolazzi G, Hollan I, Bendtzen K, Meroni PL, Borghi MO. Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors. *Autoimmun Rev*. 2020 May;19(5):102509. doi: 10.1016/j.autrev.2020.102509. Epub 2020 Mar 12.
- Ablin JN, **Sarzi-Puttini P**; 12-13 March 2020, Berlin, Germany. The Second International Congress on Controversies in Fibromyalgia. *Clin Exp Rheumatol*. 2020 Jan-Feb;38 Suppl 123(1):105-130. Epub 2020 Feb 23
- Bazzichi L, Giacomelli C, Consensi A, Giorgi V, Batticciotto A, Di Franco M, **Sarzi-Puttini P**. One year in review 2020: fibromyalgia. *Clin Exp Rheumatol*. 2020 Jan-Feb;38 Suppl 123(1):3-8. Epub 2020 Feb 21
- Salaffi F, Di Carlo M, Farah S, Marotto D, Giorgi V, **Sarzi-Puttini P**. Exercise therapy in fibromyalgia patients: comparison of a web-based intervention with usual care. *Clin Exp Rheumatol*. 2020 Jan-Feb;38 Suppl 123(1):86-93. Epub 2020 Feb 21 **(Q1, IF 3.01)**
- Salaffi F, Farah S, Di Carlo M, Sinigaglia L, Galeazzi M, Gerli R, Sonnati M, Giorgi V, **Sarzi-Puttini P**, Masullo M; Italian Society of Rheumatology (SIR) and Ministero della Salute - Direzione Generale della Programmazione Sanitaria, Roma, Italy.. The Italian Fibromyalgia Registry: a new way of using routine real-world data concerning patient-reported disease status in healthcare research and clinical practice. *Clin Exp Rheumatol*. 2020 Jan-Feb;38 Suppl 123(1):65-71. Epub 2020 Feb 12
- Giorgi V, Bongiovanni S, Atzeni F, Marotto D, Salaffi F, **Sarzi-Puttini P**. Adding medical cannabis to standard analgesic treatment for fibromyalgia: a prospective observational study. *Clin Exp Rheumatol*. 2020 Jan-Feb;38 Suppl 123(1):53-59. Epub 2020 Feb 5. **(Q1, IF 3.01)**
- Fiorenza A, Bonitta G, Gerrata E, Marino F, **Sarzi-Puttini P**, Salaffi F, Atzeni F. Assessment of enthesitis in patients with psoriatic arthritis and fibromyalgia using clinical examination and ultrasound. *Clin Exp Rheumatol*. 2020 Jan-Feb;38 Suppl 123(1):31-39. Epub 2020 Feb 11.
- Cimmino MA, Parodi M, Barbieri F, Bombardieri S, Zampogna G, Iagnocco A, Batticciotto A, Sconfienza LM, Sinigaglia L, De Benedetti F, Atzeni F, **Sarzi-Puttini P**. Dynamic Contrast-Enhanced MRI Confirms Rapid And Sustained Improvement Of Rheumatoid Arthritis Induced By Tocilizumab Treatment: An Italian Multicentre Study. *Biologics*. 2020 Feb 11;14:13-21. doi: 10.2147/BTT.S209873. eCollection 2020 **(Q2, IF 2.16)**
- Atzeni F, Nucera V, Gerrata E, Fiorenza A, Gianturco L, Corda M, **Sarzi-Puttini P**. Cardiovascular Consequences of Autoimmune Rheumatic Diseases. *Curr Vasc Pharmacol*. 2020;18(6):566-579. doi: 10.2174/157016118666200127142936
- Guerrini G, Franzetti F, Giacomelli R, Meroni L, Riva A, Scirè CA, Scrivo R, Tavio M, Agostinone A, Airò P, Atzeni F, Bartalesi F, Bazzichi L, Berardicurti O, Cassola G, Castagna A, Castelli F, Cattelan A, Citriniti G, Cristini F, De Rosa F, Fracassi E, Galloway J, La Paglia GMC, Moiola MC, Ripamonti D, Saracino A, Tani C, Tascini C, Tieghi T, Tinelli M, Zabotti A, **Sarzi-Puttini P**, Galli M. Italian recommendations for influenza and pneumococcal vaccination in adult patients with autoimmune rheumatic diseases. *Clin Exp Rheumatol*. 2020 Mar-Apr;38(2):245-256. Epub 2019 Aug 27
- Claudepierre P, Van den Bosch F, **Sarzi-Puttini P**, Vastesaegeer N, Govoni M, Kachroo S Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohort. *Int J Rheum Dis*. 2019 Jun;22(6):995-1001. doi: 10.1111/1756-185X.13526. Epub 2019 Apr 15.
- Damiani G, Pigatto PDM, Marzano AV, Rizzi M, Santus P, Radovanovic D, Loite U, Torelli L, Petrou S, **Sarzi-Puttini P**, Atzeni F, Adawi M, Bridgewood C, Bragazzi NL, Watad A, Malerba M. Malar rash is a predictor of subclinical airway inflammation in patients with systemic lupus erythematosus: a pilot study. *Clin Rheumatol*. 2019 Sep;38(9):2541-2546. doi: 10.1007/s10067-019-04536-y. Epub 2019 Apr 24.
- Galli M, Monti G, Marson P, Scaini P, Pietrogrande M, Candela M, Castelnovo L, Faggioli P, Novati P, Zani R, Mascia MT, Saccardo F, Mazzaro C, **Sarzi-Puttini P**, Sebastiani M, Quartuccio L, De Vita S. Recommendations for managing the manifestations of severe and life-threatening mixed cryoglobulinemia syndrome. *Autoimmun Rev*. 2019 Aug;18(8):778-785. doi: 10.1016/j.autrev.2019.06.008. Epub 2019 Jun 8.
- Atzeni F, **Sarzi-Puttini P**. The therapeutic journey of biologic agents: There will be an end? *Pharmacol Res*. 2019 Sep;147:104340. doi: 10.1016/j.phrs.2019.104340. Epub 2019 Jul 2.
- Atzeni F, Gianturco L, Boccassini L, **Sarzi-Puttini P**, Bonitta G, Turiel M. Noninvasive imaging methods for evaluating cardiovascular involvement in patients with rheumatoid arthritis before and after anti-TNF drug treatment. *Future Sci OA*. 2019 Jun 13;5(6):FSO396. doi: 10.2144/fsoa-2018-0108.
- Guerrini G, Franzetti F, Giacomelli R, Meroni L, Riva A, Scirè CA, Scrivo R, Tavio M, Agostinone A, Airò P, Atzeni F, Bartalesi F, Bazzichi L, Berardicurti O, Cassola G, Castagna A, Castelli F, Cattelan A, Citriniti G, Cristini F, De Rosa F, Fracassi E, Galloway J, La Paglia GMC, Moiola MC, Ripamonti D, Saracino A, Tani C, Tascini C, Tieghi T, Tinelli M, Zabotti A, **Sarzi-Puttini P**, Galli M. Italian recommendations for influenza and pneumococcal vaccination in adult patients with autoimmune rheumatic diseases. *Clin Exp Rheumatol*. 2020 Mar-Apr;38(2):245-256. Epub 2019 Aug 27.
- Talotta R, Atzeni F, **Sarzi-Puttini P**, Masala IF. Psoriatic arthritis: From pathogenesis to pharmacologic management. *Pharmacol Res*. 2019 Oct;148:104394. doi: 10.1016/j.phrs.2019.104394. Epub 2019 Sep 7.

Sarzi-Puttini P, Batticciotto A, Atzeni F, Bazzichi L, Di Franco M, Salaffi F, Marotto D, Ceribelli A, Ablin JN, Hauser W. Medical cannabis and cannabinoids in rheumatology: where are we now? *Expert Rev Clin Immunol*. 2019 Oct;15(10):1019-1032. doi: 10.1080/1744666X.2019.1665997.

Atzeni F, Nucera V, Masala IF, **Sarzi-Puttini P**, Bonitta G. IL-6 Involvement in pain, fatigue and mood disorders in rheumatoid arthritis and the effects of IL-6 inhibitor sarilumab. *Pharmacol Res*. 2019 Nov;149:104402. doi: 10.1016/j.phrs.2019.104402. Epub 2019 Sep 16.

Rubbert-Roth A, Szabó MZ, Kedves M, Nagy G, Atzeni F, **Sarzi-Puttini P**. Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents. *Autoimmun Rev*. 2019 Dec;18(12):102398. doi: 10.1016/j.autrev.2019.102398. Epub 2019 Oct 19.

Sarzi-Puttini P, Marotto D, Caporali R, Galeazzi M, Atzeni F, Hamar A, Soós B, Szekanecz Z. Biosimilars vs originators: Are they the same? *Autoimmun Rev*. 2019 Dec;18(12):102404. doi: 10.1016/j.autrev.2019.102404. Epub 2019 Oct 19.

Sarzi-Puttini P, Ablin J, Trabelsi A, Fitzcharles MA, Marotto D, Häuser W. Cannabinoids in the treatment of rheumatic diseases: Pros and cons. *Autoimmun Rev*. 2019 Dec;18(12):102409. doi: 10.1016/j.autrev.2019.102409. Epub 2019 Oct 21.

Talotta R, **Sarzi-Puttini P**, Laska MJ, Atzeni F. Retrotransposons shuttling genetic and epigenetic information from the nuclear to the mitochondrial compartment: Do they play a pathogenetic role in scleroderma? *Cytokine Growth Factor Rev*. 2019 Oct;49:42-58. doi: 10.1016/j.cytogfr.2019.10.001. Epub 2019 Oct 18.

Arnold LM, Bennett RM, Crofford LJ, Dean LE, Clauw DJ, Goldenberg DL, Fitzcharles MA, Paiva ES, Staud R, **Sarzi-Puttini P**, Buskila D, Macfarlane GJ. AAPT Diagnostic Criteria for Fibromyalgia. *J Pain*. 2019 Jun;20(6):611-628. doi: 10.1016/j.jpain.2018.10.008. Epub 2018 Nov 16. **(Q1, IF 4.62)**

Sarzi-Puttini P, Ceribelli A, Marotto D, Batticciotto A, Atzeni F. Systemic rheumatic diseases: From biological agents to small molecules. *Autoimmun Rev*. 2019 Apr 5. pii: S1568-9972(19)30087-4. doi: 10.1016/j.autrev.2018.12.009. [Epub ahead of print] Review.

Damiani G, Bragazzi NL, Grossi E, Petrou S, Radovanovic D, Rizzi M, Atzeni F, **Sarzi-Puttini P**, Santus P, Pigatto PD, Franchi C. Severe bitter taste associated with apremilast. *Dermatol Ther*. 2019 Mar 18:e12876. doi: 10.1111/dth.12876. [Epub ahead of print] No abstract available.

Rizzi M, Radovanovic D, Airoidi A, Cristiano A, Frassanito F, Gaboardi P, Saad M, Atzeni F, **Sarzi-Puttini P**, Santus P. Rationale underlying the measurement of fractional exhaled nitric oxide in systemic sclerosis patients. *Clin Exp Rheumatol*. 2019 Feb 27. [Epub ahead of print] Review

Combe B, Balsa A, **Sarzi-Puttini P**, Tony HP, de la Torre I, Rogai V, Durand F, Witt S, Zhong J, Dougados M. Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib. *Ann Rheum Dis*. 2019 Aug;78(8):1135-1138. **(Q1, IF 16.02)**

Schweiger V, Martini A, Bellamoli P, Donadello K, Schievano C, Del Balzo G, **Sarzi-Puttini P**, Parolini M, Polati E. Ultramicronized Palmitoylethanolamide (um-PEA) as add-on Treatment in Fibromyalgia Syndrome (FMS): Retrospective Observational Study on 407 Patients. *CNS Neurol Disord Drug Targets*. 2019 Feb 27. doi: 10.2174/1871527318666190227205359. [Epub ahead of print]

Arnold LM, Bennett RM, Crofford LJ, Dean LE, Clauw DJ, Goldenberg DL, Fitzcharles MA, Paiva ES, Staud R, **Sarzi-Puttini P**, Buskila D, Macfarlane GJ. Response to Wolfe. Letter to the Editor, "Fibromyalgia Criteria". *J Pain*. 2019 Feb 26. pii: S1526-5900(19)30089-6. doi: 10.1016/j.jpain.2019.02.003. [Epub ahead of print] No abstract available.

Brighina F, Curatolo M, Cosentino G, De Tommaso M, Battaglia G, **Sarzi-Puttini P**, Guggino G, Fierro B. Brain Modulation by Electric Currents in Fibromyalgia: A Structured Review on Non-invasive Approach With Transcranial Electrical Stimulation. *Front Hum Neurosci*. 2019 Feb 11;13:40. doi: 10.3389/fnhum.2019.00040. eCollection 2019. Review.

Atzeni F, **Sarzi-Puttini P**, Sebastiani M, Panetta V, Salaffi F, Iannone F, Carletto A, Foti R, Gremese E, Govoni M, Marchesoni A, Favalli E, Gorla R, Ramonda R, Ferraccioli G, Lapadula G; GISEA group Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA. *Clin Exp Rheumatol*. 2019 Feb 11. [Epub ahead of print]

Casale R, Boccia G, Symeonidou Z, Atzeni F, Batticciotto A, Salaffi F, **Sarzi-Puttini P**, Brustio PR, Rainoldi A. Neuromuscular efficiency in fibromyalgia is improved by hyperbaric oxygen therapy: looking inside muscles by means of surface electromyography. *Clin Exp Rheumatol*. 2019 Jan-Feb;37 Suppl 116(1):75-80. Epub 2019 Feb 8.

Atzeni F, Casale R, Alciati A, Masala IF, Batticciotto A, Talotta R, Gerardi MC, Salaffi F, **Sarzi-Puttini P**. Hyperbaric oxygen treatment of fibromyalgia: a prospective observational clinical study. *Clin Exp Rheumatol*. 2019 Jan-Feb;37 Suppl 116(1):63-69. Epub 2019 Feb 6. **(Q1, IF 3.01)**

Casale R, **Sarzi-Puttini P**, Botto R, Alciati A, Batticciotto A, Marotto D, Torta R. Fibromyalgia and the concept of resilience. *Clin Exp Rheumatol*. 2019 Jan-Feb;37 Suppl 116(1):105-113. Epub 2019 Feb 8. Review.

Häuser W, **Sarzi-Puttini P**, Fitzcharles MA. Fibromyalgia syndrome: under-, over- and misdiagnosis. *Clin Exp Rheumatol*. 2019 Jan-Feb;37 Suppl 116(1):90-97. Epub 2019 Feb 8. Review. PMID:

Guggino G, Schinocca C, Lo Pizzo M, Di Liberto D, Garbo D, Raimondo S, Alessandro R, Brighina F, Ruscitti P, Giacomelli R, Sireci G, Triolo G, Casale R, **Sarzi-Puttini P**, Dieli F. T helper 1 response is correlated with widespread pain, fatigue, sleeping disorders and the quality of life in patients with fibromyalgia and is modulated by hyperbaric oxygen therapy. *Clin Exp Rheumatol*. 2019 Jan-Feb;37 Suppl 116(1):81-89. Epub 2019 Feb 8.

Talotta R, **Sarzi-Puttini P**, Atzeni F. Microbial Agents as Putative Inducers of B Cell Lymphoma in Sjögren's Syndrome through an Impaired Epigenetic Control: The State-of-The-Art. *J Immunol Res*. 2019 Jan 6;2019:8567364. doi: 10.1155/2019/8567364. eCollection 2019. Review.

Talotta R, Mercurio V, Bongiovanni S, Vittori C, Boccassini L, Rigamonti F, Batticciotto A, Atzeni F, Trabatttoni D, **Sarzi-Puttini P**, Biasin M. Evaluation of salivary and plasma microRNA expression in patients with Sjögren's syndrome, and correlations with clinical and ultrasonographic outcomes *Clin Exp Rheumatol*. 2019 Jan 10. [Epub ahead of print]

- Sebastiani M, Milazzo L, Atzeni F, Vacchi C, Manfredi A, Quartuccio L, Scirè C, Gaeta GB, Lapadula G, Armignacco O, Tavio M, D'Angelo S, Meroni P, Bazzichi L, Grassi W, Mathieu A, Mastroianni C, Sagnelli E, Santantonio T, Foppa CU, Puoti M, Sarmati L, Airò P, Epis OM, Scrivo R, Gargiulo M, Riva A, Ciancio G, Zehender G, Taliani G, Meroni L, Sollima S, **Sarzi-Puttni P**, Galli M Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis. *Mod Rheumatol*. 2019 Jan 22;1-8. doi: 10.1080/14397595.2018.1558918. [Epub ahead of print] Erratum in: *Mod Rheumatol*. 2019 Apr 2;;1.
- Martini A, Schweiger V, Del Balzo G, Sartori G, Parolini M, Chinellato E, **Sarzi-Puttni P**, Polati E. Epidemiological, pharmacological and sociodemographic characterisation of a population of 386 fibromyalgic patients referred to a tertiary pain centre in Italy. *Clin Exp Rheumatol*. 2019 Jan-Feb;37 Suppl 116(1):27-38. Epub 2018 Aug 29.
- Salaffi F, Di Carlo M, Carotti M, **Sarzi-Puttni P**. The Effect of Neuropathic Pain Symptoms on Remission in Patients with Early Rheumatoid Arthritis. *Curr Rheumatol Rev*. 2019;15(2):154-161. doi: 10.2174/1573397114666180806142814. PMID: 30081788 (**Q3, IF 1.52**)
- Talotta R, Berzi A, Doria A, Batticciotto A, Ditto MC, Atzeni F, **Sarzi-Puttni P**, Trabatttoni D. The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses. *Int J Mol Sci*. 2017 Oct 12;18(10).
- Alciati A, Atzeni F, Grassi M, Caldirola D, **Sarzi-Puttni P**, Angst J, Perna G. Features of mood associated with high body weight in females with fibromyalgia. *Compr Psychiatry*. 2018 Jan;80:57-64
- Atzeni F, Pipitone N, Iaccarino L, Masala IF, Weiss R, Alciati A, Doria A, Chapmanand J, **Sarzi-Puttni P**. Rheumatic diseases and autoimmune vascular dementia. *Autoimmun Rev*. 2017 Dec;16(12):1265-1269.
- Ruscitti P, Margiotta DPE, Macaluso F, Iacono D, D'Onofrio F, Emmi G, Atzeni F, Prete M, Perosa F, **Sarzi-Puttni P**, Emmi L, Cantatore FP, Triolo G, Afeltra A, Giacomelli R, Valentini G. Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis: Results from a cross-sectional, multicenter GIRRCs (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. *Medicine (Baltimore)*. 2017 Oct;96(42):e8180.
- Favalli EG, Sinigaglia L, Becciolini A, Grosso V, Gorla R, Bazzani C, Atzeni F, **Sarzi Puttni PC**, Fusaro E, Pellerito R, Caporali R. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry. *Int J Rheum Dis*. 2018 Feb;21(2):422-430.
- Salaffi F, Di Carlo M, Iannone F, Fedele AL, Epis OM, Pellerito R, Foti R, Passiu G, Punzi L, Furini F, **Sarzi-Puttni P**, Carletto A, Gremese E, Lapadula G, Ferraccioli G. The UltraSound-Clinical Arthritis Activity (US-CLARA) index: Properties of a new composite disease activity index for rheumatoid arthritis. *Semin Arthritis Rheum*. 2018 Apr;47(5):619-629.
- Doria A, Gatto M, Iaccarino L, **Sarzi-Puttni P**. Controversies in Rheumatology and Autoimmunity: Approaching the truth by the discussion. *Autoimmun Rev*. 2018 Jan;17(1):1-3.
- Rubbert-Roth A, Atzeni F, Masala IF, Caporali R, Montecucco C, **Sarzi-Puttni P**. TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same? *Autoimmun Rev*. 2018 Jan;17(1):24-28.
- Sarzi-Puttni P**, Atzeni F, Masala IF, Salaffi F, Chapman J, Choy E. Are the ACR 2010 diagnostic criteria for fibromyalgia better than the 1990 criteria? *Autoimmun Rev*. 2018 Jan;17(1):33-35
- Galli M, Antinori S, Atzeni F, Meroni L, Riva A, Scirè C, Adorni F, Quartuccio L, Sebastiani M, Airò P, Bazzichi L, Cristini F, Del Bono V, Manfredi A, Viapiana O, De Rosa F, Favalli E, Petrelli E, Salvarani C, Govoni M, Corcione S, Scrivo R, Sarmati L, Lazzarin A, Grassi W, Mastroianni C, Gaeta GB, Ferraccioli G, Cutolo M, De Vita S, Lapadula G, Matucci-Cerinic M, Armignacco O, **Sarzi-Puttni P**. Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. *Clin Exp Rheumatol*. 2017 Nov-Dec;35(6):1018-1028 (**Q1, IF 3.01**)
- Defendenti C, Atzeni F, Malandrini S, Ardizzone S, Almasio PL, Saibeni S, Bezzio C, Bollani S, Salerno R, Declich P, Sarno Z, Bruno S, Talotta R, **Sarzi-Puttni P**. Anti-tumour necrosis factor- α antibodies and B cell homeostasis in human inflammatory bowel diseases. *Int Immunopharmacol*. 2018 Jan;54:329-335. (**Q1, IF 3.94**)
- Atzeni F, Gerardi MC, Barilaro G, Masala IF, Benucci M, **Sarzi-Puttni P**. Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review. *Expert Rev Clin Immunol*. 2018 Jan;14(1):69-82.
- Atzeni F, Gerardi MC, Masala IF, Alciati A, Batticciotto A, **Sarzi-Puttni P**. An update on emerging drugs for fibromyalgia treatment. *Expert Opin Emerg Drugs*. 2017 Dec;22(4):357-367.
- Benucci M, Damiani A, Bandinelli F, Grossi V, Infantino M, Manfredi M, Gobbi FL, **Sarzi-Puttni P**, Atzeni F. Ankylosing Spondylitis Treatment after First Anti-TNF Drug Failure. *Isr Med Assoc J*. 2018 Feb;20(2):119-122.
- Atzeni F, Corda M, Gianturco L, Porcu M, **Sarzi-Puttni P**, Turiel M. Cardiovascular Imaging Techniques in Systemic Rheumatic Diseases. *Front Med (Lausanne)*. 2018 Feb 14;5:26.
- Atzeni F, **Sarzi-Puttni P**. Neurobiological similarities between RA and fibromyalgia. *Nat Rev Rheumatol*. 2018 Jun;14(6):324-325. (**Q1, IF 18.54**)
- Talotta R, Atzeni F, Batticciotto A, Ditto MC, Gerardi MC, **Sarzi-Puttni P**. Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series. *J Med Case Rep*. 2018 Jun 3;12(1):154. (**Q3, IF 1.19**)
- Salaffi F, Di Carlo M, Carotti M, **Sarzi-Puttni P**. The subjective components of the Disease Activity Score 28-joints (DAS28) in rheumatoid arthritis patients and coexisting fibromyalgia. *Rheumatol Int*. 2018 Oct;38(10):1911-1918. (**Q2, IF 2.20**)
- Caso F, Costa L, Nucera V, Barilaro G, Masala IF, Talotta R, Caso P, Scarpa R, **Sarzi-Puttni P**, Atzeni F. From autoinflammation to autoimmunity: old and recent

findings. Clin Rheumatol. 2018 Sep;37(9):2305-2321.

Sarzi-Puttini P, Filippucci E, Adami S, Meroni PL, Batticciotto A, Idolazzi L, De Lucia O, Talavera P, Kumke T, Grassi W. Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study. Adv Ther. 2018 Aug;35(8):1153-1168. **(Q1, IF 3.26)**

Atzeni F, Talotta R, Nucera V, Marino F, Gerratana E, Sangari D, Masala IF, **Sarzi-Puttini P**. Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors. Expert Rev Clin Immunol. 2018 Nov;14(11):945-956

Salaffi F, Di Carlo M, Carotti M, **Sarzi-Puttini P**. The effect of neuropathic pain symptoms on remission in patients with early rheumatoid arthritis. Curr Rheumatol Rev. 2018 Aug 6.

Alciati A, Atzeni F, Masala IF, Cirillo M, Sciortino D, Perna G, **Sarzi-Puttini P**. Controlled-release pregabalin in the treatment of fibromyalgia. Expert Rev Neurother. 2018 Aug;18(8):617-623.

Martini A, Schweiger V, Del Balzo G, Sartori G, Parolini M, Chinellato E, **Sarzi-Puttini P**, Polati E. Epidemiological, pharmacological and sociodemographic characterisation of a population of 386 fibromyalgic patients referred to a tertiary pain centre in Italy. Clin Exp Rheumatol. 2018 Aug 29

Rizzi M, Radovanovic D, Santus P, Airoidi A, Frassanito F, Vanni S, Cristiano A, Sarzi-Puttini P, Atzeni F. Usefulness of six-minute walk test in systemic sclerosis. Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):161-167.

Conti F, Atzeni F, Massaro L, Chiara Gerardi M, Gremese E, Passiu G, Carletto A, Malavolta N, Foti R, Ramonda R, **Sarzi-Puttini P**. The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference. Rheumatology (Oxford). 2018 Oct 1;57(57 Suppl 7):vii11-vii22. **(Q1, IF 5.60)**

Scalone L, **Sarzi-Puttini P**, Sinigaglia L, Montecucco C, Giacomelli R, Lapadula G, Olivieri I, Giardino AM, Cortesi PA, Mantovani LG, Mecchia M. Patients', physicians', nurses', and pharmacists' preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases. Patient Prefer Adherence. 2018 Oct 16;12:2153-2168

Arnold LM, Bennett RM, Crofford LJ, Dean LE, Clauw DJ, Goldenberg DL, Fitzcharles MA, Paiva ES, Staud R, **Sarzi-Puttini P**, Buskila D, Macfarlane GJ. AAPT Diagnostic Criteria for Fibromyalgia. J Pain. 2018 Nov 16. pii: S1526-5900(18)30832-0.

Talotta R, Bongiovanni S, Letizia T, Rigamonti F, Ditto MC, Atzeni F, Salaffi F, Batticciotto A, Gerardi MC, Antivalle M, Vago T, Benucci M, **Sarzi-Puttini P**. Measurement of Serum Klotho in Systemic Sclerosis. Dis Markers ;2017:9545930. doi: 10.1155/2017/9545930 **(Q2, IF 2.94)**

Atzeni F, Carletto A, Foti R, Sebastiani M, Panetta V, Salaffi F, Bonitta G, Iannone F, Gremese E, Govoni M, Marchesoni A, Favalli EG, Gorla R, Ramonda R, **Sarzi-Puttini P**, Ferraccioli G, Lapadula G; GISEA group. Incidence of cancer inpatients with spondyloarthritis treated with anti-tnf drugs. Joint Bone Spine. 2017 Sep 8. pii: S1297-319X(17)30157-4.

Atzeni F, Carletto A, Foti R, Sebastiani M, Panetta V, Salaffi F, Bonitta G, Iannone F, Gremese E, Govoni M, Marchesoni A, Favalli EG, Gorla R, Ramonda R, **Sarzi-Puttini P**, Ferraccioli G, Lapadula G; GISEA group. Incidence of cancer inpatients with spondyloarthritis treated with anti-tnf drugs. Joint Bone Spine. 2017 Sep 8. pii: S1297-319X(17)30157-4.

Salaffi F, Gerardi MC, Atzeni F, Batticciotto A, Talotta R, Draghessi A, DiCarlo M, **Sarzi-Puttini P**. The influence of fibromyalgia on achieving remission inpatients with long-standing rheumatoid arthritis. Rheumatol Int 2017 Dec;37(12):2035-2042 **(Q2, IF 2.20)**

Talotta R, Atzeni F, Ditto MC, Gerardi MC, **Sarzi-Puttini P**. The Microbiome in Connective Tissue Diseases and Vasculitides: An Updated Narrative Review. J Immunol Res. 2017; Epub 2017 Aug 1.

Atzeni F, Talotta R, Masala IF, Bongiovanni S, Boccassini L, **Sarzi-Puttini P**. Biomarkers in Rheumatoid Arthritis. Isr Med Assoc J. 2017 Aug;19(8):512-516. Review.

Atzeni F, Corda M, **Sarzi-Puttini P**, Caso F, Turiel M. From Old to New Cardiovascular Complications in Ankylosing Spondylitis. Isr Med Assoc J. 2017 Aug;19(8):506-509.

Barilaro G, Francesco Masala I, Parracchini R, Iesu C, Caddia G, **Sarzi-Puttini P**, Atzeni F. The Role of Hyperbaric Oxygen Therapy in Orthopedics and Rheumatological Diseases. Isr Med Assoc J. 2017 Jul;19(7):429-434.

Manara M, Caporali R, Favalli EG, Grosso V, Atzeni F, **Sarzi-Puttini P**, Gorla R, Bazzani C, Fusaro E, Pellerito R, Rocchetta PA, Sinigaglia L. Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry. Clin Exp Rheumatol. 2017 Sep-Oct;35(5):804-809. Epub 2017 Jul 27.

Giacomelli R, Afeltra A, Alunno A, Baldini C, Bartoloni-Bocci E, Berardicurti O, Carubbi F, Cauli A, Cervera R, Ciccio F, Cipriani P, Conti F, De Vita S, Di Benedetto P, Doria A, Drosos AA, Favalli EG, Gandolfo S, Gatto M, Grembale RD, Liakouli V, Lories R, Lubrano E, Lunardi C, Margiotta DPE, Massaro L, Meroni P, Minniti A, Navarini L, Pendolino M, Perosa F, Pers JO, Prete M, Priori R, Puppo F, Quartuccio L, Ruffatti A, Ruscitti P, Russo B, **Sarzi-Puttini P**, Shoenfeld Y, Somarakis GA, Spinelli FR, Tinazzi E, Triolo G, Ursini F, Valentini G, Valesini G, Vettori S, Vitali C, Tzioufas AG. International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)? The unmet needs and the clinical grey zone in autoimmune disease management. Autoimmun Rev. 2017 Sep;16(9):911-924.

Salaffi F, Atzeni F, Talotta R, Di Carlo M, **Sarzi-Puttini P**. Earthquake vulnerability of fibromyalgia patients: six-month follow-up after the catastrophic disasters in central Italy. Clin Exp Rheumatol. 2017 May-Jun;35 Suppl 105(3):93-99. **(Q1, IF 3.01)**

- Alciati A, Atzeni F, Grassi M, Caldirola D, Riva A, **Sarzi-Puttini P**, Perna G. Childhood adversities in patients with fibromyalgia: are they related to comorbid lifetime major depression? *Clin Exp Rheumatol*. 2017 May-Jun;35 Suppl105(3):112-118. Epub 2017 Jun 29.
- Talotta R, Bazzichi L, Di Franco M, Casale R, Batticciotto A, Gerardi MC, **Sarzi-Puttini P**. One year in review 2017: fibromyalgia. *Clin Exp Rheumatol*. 2017 May-Jun;35 Suppl 105(3):6-12. Epub 2017 Jun 28.
- Masala IF, Caso F, **Sarzi-Puttini P**, Salaffi F, Atzeni F. Acute and chronic pain in orthopaedic and rheumatologic diseases: mechanisms and characteristics. *Clin Exp Rheumatol*. 2017 May-Jun;35 Suppl 105(3):127-131. Epub 2017 Jun 29.
- Schweiger V, Del Balzo G, Raniero D, De Leo D, Martini A, **Sarzi-Puttini P**, Polati E. Current trends in disability claims due to fibromyalgia syndrome. *Clin Exp Rheumatol*. 2017 May-Jun;35 Suppl 105(3):119-126. Epub 2017 Jun 29.
- Rizzi M, Radovanovic D, Santus P, Airoidi A, Frassanito F, Vanni S, Cristiano A, Masala IF, **Sarzi-Puttini P**. Influence of autonomic nervous system dysfunction in the genesis of sleep disorders in fibromyalgia patients. *Clin Exp Rheumatol*. 2017 May-Jun;35 Suppl 105(3):74-80. Epub 2017 Jun 29.
- Sebastiani M, Atzeni F, Milazzo L, Quartuccio L, Scirè C, Gaeta GB, Lapadula G, Armignacco O, Tavio M, Olivieri I, Meroni P, Bazzichi L, Grassi W, Mathieu A, Mastroianni C, Sagnelli E, Santantonio T, Uberti Foppa C, Puoti M, Sarmati L, Airò P, Epis OM, Scrivo R, Gargiulo M, Riva A, Manfredi A, Ciancio G, Zehender G, Taliani G, Meroni L, Sollima S, **Sarzi-Puttini P**, Galli M. Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. *Joint Bone Spine*. 2017 Oct;84(5):525-530.
- Caporali R, Idolazzi L, Bombardieri S, Ferraccioli G, Gerli R, Govoni M, Matucci Cerinic M, Pomponio G, Salaffi F, Tirri R, Benaglio F, Bianchino L, **Sarzi-Puttini P**; TRUST study investigators. Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study. *Clin Exp Rheumatol*. 2017 Nov-Dec;35(6):919-928. (Q1, IF 3.01)
- Codullo V, Iannone F, Sinigaglia L, Favalli EG, **Sarzi-Puttini P**, Atzeni F, Ferraccioli G, Gremese E, Carletto A, Giollo A, Govoni M, Bergossi F, Galeazzi M, Cantarini L, Salaffi F, Di Carlo M, Bazzani C, Pellerito R, Sebastiani M, Ramonda R, Lapadula G, Caporali R. Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. *Clin Exp Rheumatol*. 2017 Jul-Aug;35(4):660-665. Epub 2017 May 8. PMID: 28516879.
- Macfarlane GJ, Kronisch C, Atzeni F, Häuser W, Choy EH, Amris K, Branco J, Dincer F, Leino-Arjas P, Longley K, McCarthy G, Makri S, Perrot S, **Sarzi-Puttini P**, Taylor A, Jones GT. EULAR recommendations for management of fibromyalgia. *Ann Rheum Dis*. 2017 Dec;76(12):e54. doi: 10.1136/annrheumdis-2017-211587. Epub 2017 May 5. PMID: 28476880.
- Galli M, Oreni L, Saccardo F, Castelnovo L, Filippini D, Marson P, Mascia MT, Mazzaro C, Origgi L, Ossi E, Pietrogrande M, Pioltelli P, Quartuccio L, Scarpato S, Sollima S, Riva A, Fraticelli P, Zani R, Giuggioli D, Sebastiani M, **Sarzi-Puttini P**, Gabrielli A, Zignego AL, Scaini P, Ferri C, De Vita S, Monti G. HCV-unrelated cryoglobulinaemic vasculitis: the results of a prospective observational study by the Italian Group for the Study of Cryoglobulinaemias (GISC). *Clin Exp Rheumatol*. 2017 Mar-Apr;35 Suppl 103(1):67-76. Epub 2017 Apr 19.
- Atzeni F, Masala IF, di Franco M, **Sarzi-Puttini P**. Infections in rheumatoid arthritis. *Curr Opin Rheumatol*. 2017 Jul;29(4):323-330. (Q1; IF 4.00)
- Dean LE, Arnold L, Crofford L, Bennett R, Goldenberg D, Fitzcharles MA, Paiva ES, Staud R, Clauw D, **Sarzi-Puttini P**, Jones GT, Ayorinde A, Fluß E, Beasley M, Macfarlane GJ. The impact of moving from a widespread to multi-site pain definition on other fibromyalgia symptoms. *Arthritis Care Res (Hoboken)*. 2017 Feb 9. (Q1, IF 4.05)
- Grossi V, Infantino M, Meacci F, Bellio E, Bellio V, Ciotta G, Priami F, **Sarzi-Puttini P**, Atzeni F, Li Gobbi F, Damiani A, Benucci M, Manfredi M. Comparison of methods and TAT assessment: Volumetric AQUIOS CL and bead-based FACS CANTO II cytometers. *Cytometry B Clin Cytom*. 2017 Jan 20.
- Monti S, Klersy C, Gorla R, **Sarzi-Puttini P**, Atzeni F, Pellerito R, Fusaro E, Paolazzi G, Rocchetta PA, Favalli EG, Marchesoni A, Caporali R. Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. *Clin Rheumatol*. 2017 Apr;36(4):753-761.
- Talotta R, Atzeni F, Batticciotto A, Benucci M, Bongiovanni S, **Sarzi-Puttini P**. Biological Agents In Rheumatoid Arthritis: A Cross-Link Between Immune Tolerance And Immune Surveillance. *Curr Rheumatol Rev*. 2016 Dec 30.
- Van Riel P, Alten R, Combe B, Abduganieva D, Bousquet P, Courtenay M, Curiale C, Gómez-Centeno A, Haugeberg G, Leeb B, Puolakka K, Ravelli A, Rintelen B, **Sarzi-Puttini P**. Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools. *RMD Open*. 2016 Nov 24;2(2):e000302. eCollection 2016. (Q1, Scopus CiteScore: 5.4)
- Atzeni F, Benucci M, Talotta R, Masala IF, **Sarzi-Puttini P**, Govoni M. What are the dangers of biological therapy discontinuation or dose reduction strategies when treating rheumatoid arthritis? *Expert Rev Clin Pharmacol*. 2016 Nov;9(11):1403-1411.
- Atzeni F, Gianturco L, Colombo C, Ricci C, **Sarzi-Puttini P**, Turiel M. Can speckle tracking echocardiography detect subclinical left ventricular dysfunction in patients with primary Sjögren's syndrome? *Clin Exp Rheumatol*. 2017 Jan-Feb;35(1):173. Epub 2016 Oct 3.
- Gerardi MC, Atzeni F, Batticciotto A, Di Franco M, Rizzi M, **Sarzi-Puttini P**. The safety of pregabalin in the treatment of fibromyalgia. *Expert Opin Drug Saf*. 2016 Oct 11:1-8.
- Benucci M, Gobbi FL, Bandinelli F, Damiani A, Infantino M, Grossi V, Manfredi M, Parisi S, Fusaro E, Batticciotto A, **Sarzi-Puttini P**, Atzeni F, Meacci F. Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study. *Immunol Res*. 2017 Feb;65(1):419-422.

Infantino M, Meacci F, Grossi V, Manfredi M, Li Gobbi F, **Sarzi-Puttini P**, Atzeni F, Benucci M. The clinical impact of Anti-DFS70 antibodies in undifferentiated connective tissue disease: case reports and a review of the literature. *Immunol Res.* 2017 Feb;65(1):293-295.

Iannone F, Sinigaglia L, Favalli EG, **Sarzi-Puttini P**, Atzeni F, Caporali R, Codullo V, Ferraccioli G, Gremese E, Carletto A, Giollo A, Govoni M, Bergossi F, Galeazzi M, Cantarini L, Salaffi F, Di Carlo M, Bazzani C, Pellerito R, Sebastiani M, Ramonda R, Lapadula G. Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high remission together with normal function ability. *Clin Rheumatol.* 2016 Nov;35(11):2649-2656.

Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Häuser W, Fluß E, Choy E, Kosek E, Amris K, Branco J, Dincer F, Leino-Arjas P, Longley K, McCarthy GM, Makri S, Perrot S, **Sarzi-Puttini P**, Taylor A, Jones GT. EULAR revised recommendations for the management of fibromyalgia. *Ann Rheum Dis.* 2017 Feb;76(2):318-328. doi:10.1136/annrheumdis-2016-209724. Epub 2016 Jul 4.

Batticiotto A, Ravasio R, Riva M, **Sarzi-Puttini P**. Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate. *Adv Ther.* 2016 Aug;33(8):1360-73. doi: 10.1007/s12325-016-0372-z.. **(Q1, IF 3.26)**

Grossi V, Infantino M, Manfredi M, Meacci F, Bellio E, Bellio V, Gobbi FL, Ugolini S, Catani S, **Sarzi-Puttini P**, Atzeni F, Benucci M. A Proposed Serum Calprotectin IgG Cut-Off Level for Diagnosing Inflammatory Arthritis. *Curr Rheumatol Rev.* 2017;13(2):93-97

Caruso I, Santandrea S, Gismondo M, Lombardi A, Montrone F, Caruso EM, **Sarzi-Puttini P**. Vaccination with endosomal unknown epitopes produces therapeutic response in rheumatoid arthritis patients and modulates adjuvant arthritis of rats. *J Transl Med.* 2016 Jun 7;14(1):162. **(Q1; IF 4.97)**

Salaffi F, Mozzani F, Draghessi A, Atzeni F, Catellani R, Ciapetti A, Di Carlo M, **Sarzi-Puttini P**. Identifying the symptom and functional domains in patients with fibromyalgia: results of a cross-sectional Internet-based survey in Italy. *J Pain Res.* 2016 May 13;9:279-86. **(Q1; IF 2.58)**

Rovisco J, Duarte C, Batticiotto A, Sarzi-Puttini P, Draghessi A, Portela F, Gutierrez M. Erratum to: Hidden musculoskeletal involvement in inflammatory bowel disease: a multicenter ultrasound study. *BMC Musculoskelet Disord.* 2016 Jun 1;17(1):241.

Atzeni F, Batticiotto A, Masala IF, Talotta R, Benucci M, **Sarzi-Puttini P**. Infections and Biological Therapy in Patients with Rheumatic Diseases. *Isr Med Assoc J.* 2016 Mar-Apr;18(3-4):164-7.

Atzeni F, Grillo E, Masala IF, **Sarzi-Puttini P**, Jones GT. Do Anti-TNF Blockers Increase the Risk of Lung Involvement in Patients with Ankylosing Spondylitis or Psoriatic Arthritis? A Systematic Review. *Isr Med Assoc J.* 2016 Mar-Apr;18(3-4):154-5.

Bazzichi L, Giacomelli C, Consensi A, Atzeni F, Batticiotto A, Di Franco M, Casale R, **Sarzi-Puttini P**. One year in review 2016: fibromyalgia. *Clin Exp Rheumatol.* 2016 Mar-Apr;34(2 Suppl 96):S145-9. Epub 2016 Apr 22.

Truini A, Tinelli E, Gerardi MC, Calistri V, Iannuccelli C, La Cesa S, Tarsitani L, Mainero C, **Sarzi-Puttini P**, Cruccu G, Caramia F, Di Franco M. Abnormal resting state functional connectivity of the periaqueductal grey in patients with fibromyalgia. *Clin Exp Rheumatol.* 2016 Mar-Apr;34(2 Suppl 96):S129-33.

Rizzi M, Atzeni F, Airolidi A, Masala IF, Frassanito F, Salaffi F, Macaluso C, **Sarzi-Puttini P**. Impaired lung transfer factor in fibromyalgia syndrome. *Clin Exp Rheumatol.* 2016 Mar-Apr;34(2 Suppl 96):S114-9. **(Q1, IF 3.01)**

Alciati A, Caldirola D, **Sarzi-Puttini P**, Atzeni F, Grassi M, Perna G. Is panic disorder associated with clinical severity of fibromyalgia? A preliminary study in a tertiary-care centre. *Clin Exp Rheumatol.* 2016 Mar-Apr;34(2 Suppl 96):S99-105. Epub 2016 Apr 22.

Iannone F, Carlino G, Marchesoni A, **Sarzi-Puttini P**, Gorla R, Lapadula G, GISEA (Gruppo Italiano di Studio sulle Early Arthritides). Early clinical response predicts low disease activity at one year in rheumatoid arthritis patients on treatment with certolizumab in real-life settings. An appraisal of the Italian registry GISEA. *Joint Bone Spine.* 2016 Dec;83(6):721-725.

Talotta R, Atzeni F, **Sarzi Puttini P**. Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report. *BMC Pharmacol Toxicol.* 2016 Apr 21;17:17. **(Q2; IF 1.77)**

Bateman L, **Sarzi-Puttini P**, Burbridge CL, Landen JW, Masters ET, Bhadra Brown P, Scavone JM, Emir B, Vissing RS, Clair AG, Pauer LR. Burden of illness in fibromyalgia patients with comorbid depression. *Clin Exp Rheumatol.* 2016 Mar-Apr;34(2 Suppl 96):S106-13.

Benucci M, Meacci F, Grossi V, Infantino M, Manfredi M, Bellio E, Bellio V, Li Gobbi F, Bazzichi L, Moscato P, Caputo D, Saviola G, Talotta R, **Sarzi-Puttini P**, Atzeni F. Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab. *Biologics.* 2016 Mar 11;10:53-8.

Ramonda R, Marchesoni A, Carletto A, Bianchi G, Cutolo M, Ferraccioli G, Fusaro E, De Vita S, Galeazzi M, Gerli R, Matucci-Cerinic M, Minisola G, Montecucco C, Pellerito R, Salaffi F, Paolazzi G, **Sarzi-Puttini P**, Scarpa R, Bagnato G, Triolo G, Valesini G, Punzi L, Olivieri I; ATLANTIS study group. Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey. *Arthritis Res Ther.* 2016 Apr 1;18:78.

Legnani D, Rizzi M, Sarzi-Puttini P, Cristiano A, La Spina T, Frassanito F, Airolidi A, Atzeni F. Diffusing Pulmonary Capacity Measured During Effort: A Possible Early Marker of Pulmonary Involvement in Systemic Sclerosis. *Isr Med Assoc J.* 2015 Dec;17(12):739-43. PubMed PMID: 26897974.

Varisco V, Viganò M, Batticiotto A, Lampertico P, Marchesoni A, Gibertini P, Pellerito R, Rovera G, Caporali R, Todoerti M, Covelli M, Notarnicola A, Atzeni F, **Sarzi-Puttini P**. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study. *J Rheumatol.* 2016 May;43(5):869-74. PubMed PMID: 26879359 **(Q1; IF 3.18)**

Rovisco J, Duarte C, Batticciotto A, **Sarzi-Puttni P**, Dragresshi A, Portela F, Gutierrez M. Hidden musculoskeletal involvement in inflammatory bowel disease: a multicenter ultrasound study. *BMC Musculoskelet Disord*. 2016 Feb 16;17(1):84. doi: 10.1186/s12891-016-0932-z. PubMed PMID: 26879247; PubMed Central PMCID:PMC4754919.

Gerardi MC, Batticciotto A, Talotta R, Di Franco M, Atzeni F, **Sarzi-Puttni P**. Novel pharmaceutical options for treating fibromyalgia. *Expert Rev Clin Pharmacol*. 2016 Feb 16:1-7. [Epub ahead of print] PubMed PMID: 26794309.

Infantino M, Meacci F, Grossi V, Benucci M, Morozzi G, Tonutti E, Tampoia M, Ott A, Meyer W, Atzeni F, **Sarzi-Puttni P**, Manfredi M, Bizzaro N. Serological epitope profile of anti-Ro52-positive patients with systemic autoimmune rheumatic diseases. *Arthritis Res Ther*. 2015 Dec 17;17:365.

Tamirou F, Lauwerys BR, Dall'Era M, Mackay M, Rovin B, Cervera R, Houssiau FA, Abramowicz D, de Bruxelles L, Atzeni F, Blockmans D, Danieli MG, De Clercq L, D'Cruz D, Guttierrez Mdel M, Garrido Ede R, Gilboe IM, de Keyser F, Delahousse M, Espinosa G, Fiehn C, Golstein M, Guillemin L, Hirsch M, Karras A, Lang P, le Guern V, Marchal M, Marinho A, Max R, Peeters P, Petera P, Petrovic R, Quémener T, Raeman F, Remy P, Ravelingien I, **Sarzi-Puttni P**, Sangle S, Tektonidou M, de Santis LV, Vasconcelos C, Verresen L, Weiss L, Westhovens R. A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. *Lupus Sci Med*. 2015 Nov 12;2(1):e000123. (Q1; IF 2.95)

Padovan M, Filippini M, Tincani A, Lanciano E, Bruschi E, Epis O, Garau P, Mathieu A, Celletti E, Giani L, Tomietto P, Atzeni F, **Sarzi Puttni P**, Zuliani F, De Vita S, Francesco T, Grilli A, Puoti M, Govoni M. Safety of abatacept in rheumatoid arthritis with serological evidence of past or present hepatitis B virus infection. *Arthritis Care Res (Hoboken)*. 2016 Jun;68(6):738-43.

Atzeni F, Costa L, Caso F, Scarpa R, **Sarzi-Puttni P**. Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis. *J Rheumatol Suppl*. 2015 Nov;93:79-81

Sarzi-Puttni P, Varisco V, Ditto MC, Benucci M, Atzeni F. Psoriatic Arthritis Registries. *J Rheumatol Suppl*. 2015 Nov;93:30-2

Defendenti C, **Sarzi-Puttni P**, Saibeni S, Bollani S, Bruno S, Almasio PL, Declich P, Atzeni F. Significance of serum IL-9 levels in inflammatory bowel disease. *Int J Immunopathol Pharmacol*. 2015 Dec;28(4):569-75

Rizzi M, **Sarzi-Puttni P**, Airoidi A, Antivale M, Battellino M, Atzeni F. Performance capacity evaluated using the 6-minute walk test: 5-year results in patients with diffuse systemic sclerosis and initial interstitial lung disease. *Clin Exp Rheumatol*. 2015 Jul-Aug;33(4 Suppl 91):S142-

Talotta R, Berzi A, Atzeni F, Batticciotto A, Clerici M, **Sarzi-Puttni P**, Trabattini D. Paradoxical Expansion of Th1 and Th17 Lymphocytes in Rheumatoid Arthritis Following Infliximab Treatment: a Possible Explanation for a Lack of Clinical Response. *J Clin Immunol*. 2015 Aug;35(6):550-7

Salaffi F, **Sarzi-Puttni P**, Atzeni F. How to measure chronic pain: New concepts. *Best Pract Res Clin Rheumatol*. 2015 Feb;29(1):164-86

Scarpato S, Atzeni F, **Sarzi-Puttni P**, Brucato A, Quartuccio L, Pietrogrande M, Monti G, Galli M; Italian Group for Study of Cryoglobulinaemia (GISC). Pain management in cryoglobulinaemic syndrome. *Best Pract Res Clin Rheumatol*. 2015 Feb;29(1):77-89

Casale R, Atzeni F, Masala IF, **Sarzi-Puttni P**. The words of pain in complex regional pain syndrome. *Best Pract Res Clin Rheumatol*. 2015 Feb;29(1):71-6

Di Franco M, Bazzichi L, Casale R, **Sarzi-Puttni P**, Atzeni F. Pain in systemic connective tissue diseases. *Best Pract Res Clin Rheumatol*. 2015 Feb;29(1):53-62. doi: 10.1016/j.berh.2015.05.006. Epub 2015 Jun 6.

Atzeni F, Masala IF, Salaffi F, Di Franco M, Casale R, **Sarzi-Puttni P**. Pain in systemic inflammatory rheumatic diseases. *Best Pract Res Clin Rheumatol*. 2015 Feb;29(1):42-52. doi: 10.1016/j.berh.2015.04.016. Epub 2015 May 19.

Sarzi-Puttni P, Atzeni F, Clauw DJ, Perrot S. The impact of pain on systemic rheumatic diseases. *Best Pract Res Clin Rheumatol*. 2015 Feb;29(1):1-5. doi:10.1016/j.berh.2015.05.004. Epub 2015 Jun 27.

Atzeni F, **Sarzi-Puttni P**. Autoimmune hepatitis and allergic reactions during anti-TNF α treatment. *Isr Med Assoc J*. 2015 Apr;17(4):247-8.

Arnold LM, **Sarzi-Puttni P**, Arseneault P, Khan T, Bhadra Brown P, Clair A, Scavone JM, Driscoll J, Landen J, Pauer L. Efficacy and Safety of Pregabalin in Patients with Fibromyalgia and Comorbid Depression Taking Concurrent Antidepressant Medication: A Randomized, Placebo-controlled Study. *J Rheumatol*. 2015 Jul;42(7):1237-44.

Zanini C, **Sarzi-Puttni P**, Atzeni F, Di Franco M, Rubinelli S. Building bridges between doctors and patients: the design and pilot evaluation of a training session in argumentation for chronic pain experts. *BMC Med Educ*. 2015 May 19;15:89.

Atzeni F, Gianturco L, Talotta R, Varisco V, Ditto MC, Turiel M, **Sarzi-Puttni P**. Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: cause for concern? *Immunotherapy*. 2015;7(4):353-61.

Gianturco L, Bodini BD, Atzeni F, Colombo C, Stella D, **Sarzi-Puttni P**, Drago L, Galaverna S, Turiel M. Cardiovascular and autoimmune diseases in females: The role of microvasculature and dysfunctional endothelium. *Atherosclerosis*. 2015 Jul;241(1):259-63.

Benucci M, Oliveto B, Manfredi M, Meacci F, Infantino M, Li Gobbi F, **Sarzi-Puttni P**, Marcassa C, Atzeni F. Polymyalgia rheumatica: inflammation suppression with low dose of methylprednisolone or modified-release prednisone. *Eur Rev Med Pharmacol Sci*. 2015;19(5):745-51.

Casale R, Atzeni F, **Sarzi-Puttni P**. The therapeutic approach to complex regional pain syndrome: light and shade. *Clin Exp Rheumatol*. 2015 Jan-Feb;33(1 Suppl 88):S126-39. Epub 2015 Mar 18. PMID: 25786054.

- Talotta R, Atzeni F, Bazzichi L, Giacomelli C, Di Franco M, Salaffi F, **Sarzi-Puttini P**. Algo-dysfunctional syndromes: a critical digest of the recent literature. *Clin Exp Rheumatol*. 2015 Jan-Feb;33(1 Suppl 88):S102-8. Epub 2015 Mar 18. PMID: 25786051.
- Salaffi F, Ciapetti A, Gasparini S, Atzeni F, **Sarzi-Puttini P**, Baroni M. Web/Internet-based telemonitoring of a randomized controlled trial evaluating the time-integrated effects of a 24-week multicomponent intervention on key health outcomes in patients with fibromyalgia. *Clin Exp Rheumatol*. 2015 Jan-Feb;33(1 Suppl 88):S93-101.
- Leombruni P, Miniotti M, Colonna F, Sica C, Castelli L, Bruzzone M, Parisi S, Fusaro E, **Sarzi-Puttini P**, Atzeni F, Torta RG. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. *Clin Exp Rheumatol*. 2015 Jan-Feb;33(1 Suppl 88):S82-5.
- Truini A, Gerardi MC, Di Stefano G, La Cesa S, Iannuccelli C, Pepe A, **Sarzi-Puttini P**, Cruccu G, Di Franco M. Hyperexcitability in pain matrices in patients with fibromyalgia. *Clin Exp Rheumatol*. 2015 Jan-Feb;33(1 Suppl 88):S68-72.
- Zamunér AR, Barbic F, Dipaola F, Bulgheroni M, Diana A, Atzeni F, Marchi A, **Sarzi-Puttini P**, Porta A, Furlan R. Relationship between sympathetic activity and pain intensity in fibromyalgia. *Clin Exp Rheumatol*. 2015 Jan-Feb;33(1 Suppl 88):S53-7.
- Casale R, Atzeni F, **Sarzi-Puttini P**. From Mitchell's causalgia to complex regional pain syndromes: 150 years of definitions and theories. *Clin Exp Rheumatol*. 2015 Jan-Feb;33(1 Suppl 88):S7-13. Epub 2015 Mar 17. PMID: 25786040.
- Infantino M, Meacci F, Bentow C, Martis P, Benucci M, Afeltra A, Rigon A, Atzeni F, **Sarzi-Puttini P**, Manfredi M, Mahler M. Clinical comparison of QUANTA Flash dsDNA chemiluminescent immunoassay with four current assays for the detection of anti-dsDNA autoantibodies. *J Immunol Res*. 2015;2015:902821. doi: 10.1155/2015/902821. Epub 2015 Jan 5. PMID: 25759849; PMCID: PMC4352420.
- Tamirou F, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Fiehn C, Ayala Gutierrez Mdel M, Gilboe IM, Tektonidou M, Blockmans D, Ravelingien I, le Guern V, Depresseux G, Guillevin L, Cervera R, Houssiau FA; MAINTAIN Nephritis Trial Group (co-investigators: **Sarzi-Puttini P**). Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. *Ann Rheum Dis*. 2016 Mar;75(3):526-31. doi: 10.1136/annrheumdis-2014-206897. Epub 2015 Mar 10. PMID: 25757867; PMCID: PMC4789692.
- Benucci M, Li Gobbi F, Meacci F, Manfredi M, Infantino M, Severino M, Testi S, **Sarzi-Puttini P**, Ricci C, Atzeni F. Antidrug antibodies against TNF-blocking agents: correlations between disease activity, hypersensitivity reactions, and different classes of immunoglobulins. *Biologics*. 2015 Feb 17;9:7-12. doi: 10.2147/BTT.S69606. PMID: 25733803; PMCID: PMC4337417.
- Benucci M, Meacci F, Manfredi M, Gobbi FL, Infantino M, Ricci C, **Sarzi-Puttini P**, Atzeni F. Can Tocilizumab Decrease Cartilage Oligomeric Matrix Protein Levels and Disease Activity in Patients with Long-Standing Rheumatoid Arthritis? *Curr Rheumatol Rev*. 2015 Feb 9. Epub ahead of print. PMID: 25666883.
- Sarzi-Puttini P**, Atzeni F. New biological treatments for psoriatic arthritis. *Isr Med Assoc J*. 2014 Oct;16(10):643-5.
- Cassisi G, Ceccherelli F, Atzeni F, **Sarzi-Puttini P**. Reply to: mast cells in fibromyalgia. *Clin Exp Rheumatol*. 2015 Jan-Feb;33(1 Suppl 88):S140. Epub 2014 Nov 7. PMID: 25438037.
- Atzeni F, Sebastiani M, Ricci C, Celano A, Gremese E, Iannone F, Meroni PL, Minghetti P, **Sarzi-Puttini P**, Ferraccioli G, Lapadula G. Position paper of Italian rheumatologists on the use of biosimilar drugs. *Clin Exp Rheumatol*. 2015 Jan-Feb;33(1):1-4.
- Jones GT, Atzeni F, Beasley M, Flüß E, **Sarzi-Puttini P**, Macfarlane GJ. The prevalence of fibromyalgia in the general population: a comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria. *Arthritis Rheumatol*. 2015 Feb;67(2):568-75. (Q1; IF 9.00)
- Giacomelli R, Gorla R, Trotta F, Tirri R, Grassi W, Bazzichi L, Galeazzi M, Matucci-Cerinic M, Scarpa R, Cantini F, Gerli R, Lapadula G, Sinigaglia L, Ferraccioli G, Olivieri I, Ruscitti P, **Sarzi-Puttini P**. Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study. *Rheumatology (Oxford)*. 2015 May;54(5):792-7(Q1, IF 5.60)
- Filippini M, Bazzani C, Atzeni F, **Sarzi Puttini P**, Marchesoni A, Favalli EG, Caporali R, Cavagna L, Gorla R. Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: long-term real-life data from the Lorhen Registry. *Biomed Res Int*. 2014;2014:416892. doi: 10.1155/2014/416892. Epub 2014 Jul 6. PMID: 25110678; PMCID: PMC4109221
- Sebastiani M, Anelli MG, Atzeni F, Bazzani C, Farina I, Fedele AL, Favalli EG, Fineschi I, Cino N, Dal Forno I, Gasparini S, Cassarà E, Giardina R, Bruschi E, Addimanda O, Cassone G, Lopriore S, **Sarzi-Puttini P**, Filippini M, Pignatti F, Gremese E, Biggioggero M, Manganelli S, Amato G, Caimmi C, Salaffi F, Iannone F, Ferri C, Sandri G, Lapadula G, Gorla R, Govoni M, Ferraccioli G, Marchesoni A, Galeazzi M, Foti R, Carletto A, Cantini F, Triolo G, Epis OM, Salvarani C; Italian Study Group on Early Arthritides (GISEA). Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register. *Joint Bone Spine*. 2014 Dec;81(6):508-12.
- Zanini C, **Sarzi-Puttini P**, Atzeni F, Di Franco M, Rubinelli S. Doctors' insights into the patient perspective: a qualitative study in the field of chronic pain. *Biomed Res Int*. 2014;2014:514230. (Q1; IF 1.57)
- Infantino M, Manfredi M, Meacci F, **Sarzi-Puttini P**, Ricci C, Atzeni F, Benucci M. Anti-citrullinated peptide antibodies and rheumatoid factor isotope in the diagnosis of rheumatoid arthritis: an assessment of combined tests. *Clin Chim Acta*. 2014 Sep 25;436:237-42.
- Sarzi-Puttini P**, Atzeni F. Fibromyalgia: a never-ending story of central and peripheral pain mechanisms. *Arthritis Rheumatol*. 2014 Jul;66(7):1687-8.
- Sozzani S, Abbracchio MP, Annese V, Danese S, De Pittà O, De Sarro G, Maione S, Olivieri I, Parodi A, **Sarzi-Puttini P**. Chronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review. *Autoimmunity*. 2014 Aug;47(5):287-306. doi: 10.3109/08916934.2014.897333. Epub 2014 Apr 3. PMID: 24697663.

Cogliati C, Antiville M, Torzillo D, Birocchi S, Norsa A, Bianco R, Costantino G, Ditto MC, Battellino M, **Sarzi-Puttini PC**, Montano N. Standard and pocket-size lung ultrasound devices can detect interstitial lung disease in rheumatoid arthritis patients. *Rheumatology (Oxford)*. 2014 Aug;53(8):1497-503.

Matsuura E, Atzeni F, **Sarzi-Puttini P**, Turiel M, Lopez LR, Nurmohamed MT. Is atherosclerosis an autoimmune disease? *BMC Med*. 2014 Mar 18;12:47. doi: 10.1186/1741-7015-12-47. PMID: 24642015; PMCID: PMC3984678.

Atzeni F, **Sarzi-Puttini P**, Signorello MC, Gianturco L, Stella D, Boccassini L, Ricci C, Bodini BD, Batticciotto A, De Gennaro-Colonna V, Drago L, Turiel M. New parameters for identifying subclinical atherosclerosis in patients with primary Sjögren's syndrome: a pilot study. *Clin Exp Rheumatol*. 2014 May-Jun;32(3):361-8.

Langhorst J, Häuser W, Lauche R, Perrot S, Alegre C, **Sarzi-Puttini P**. Complementary and alternative medicine for the treatment of fibromyalgia. *Evid Based Complement Alternat Med*. 2014;2014:408436.

Salaffi F, De Angelis R, Carotti M, Gutierrez M, **Sarzi-Puttini P**, Atzeni F. Fibromyalgia in patients with axial spondyloarthritis: epidemiological profile and effect on measures of disease activity. *Rheumatol Int*. 2014 Aug;34(8):1103-10.

Giacomelli C, Sernissi F, **Sarzi-Puttini P**, Di Franco M, Atzeni F, Bazzichi L. Fibromyalgia: a critical digest of the recent literature. *Clin Exp Rheumatol*. 2013 Nov-Dec;31(6 Suppl 79):S153-7. Epub 2013 Dec 18. PMID: 24373373.

Cassisi G, Ceccherelli F, Atzeni F, **Sarzi-Puttini P**. Complementary and alternative medicine in fibromyalgia: a practical clinical debate of agreements and contrasts. *Clin Exp Rheumatol*. 2013 Nov-Dec;31(6 Suppl 79):S134-52. Epub 2013 Dec 16. PMID: 24373372.

Emery P, Gottenberg JE, Rubbert-Roth A, **Sarzi-Puttini P**, Choquette D, Taboada VM, Barile-Fabris L, Moots RJ, Ostor A, Andrianakos A, Gemmen E, Mpofu C, Chung C, Gylvin LH, Finckh A. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. *Ann Rheum Dis*. 2015 Jun;74(6):979-84. **(Q1, IF 16.02)**

Monti G, Saccardo F, Castelnovo L, Novati P, Sollima S, Riva A, **Sarzi-Puttini P**, Quartuccio L, De Vita S, Galli M. Prevalence Salaffi F, Giorgi V, Sirotti S, Bongiovanni S, Farah S, Bazzichi L, Marotto D, Atzeni F, Rizzi M, Batticciotto A, Lombardi G, Galli M, **Sarzi-Puttini P**. The effect of novel coronavirus disease-2019 (COVID-19) on fibromyalgia syndrome. *Clin Exp Rheumatol*. 2020 Nov 16. Online ahead of print. **(Q1, IF 3.01)**

Alciati A, Atzeni F, Caldirola D, Perna G, **Sarzi-Puttini P**. The Co-Morbidity between Bipolar and Panic Disorder in Fibromyalgia Syndrome *J Clin Med*. 2020 Nov 10;9(11):E3619. doi: 10.3390/jcm9113619 **(Q1, IF 3.03)**

Salaffi F, Carotti M, Tardella M, Borgheresi A, Agostini A, Minorati D, Marotto D, Di Carlo M, Galli M, Giovagnoni A, **Sarzi-Puttini P**. The role of a chest computed tomography severity score in coronavirus disease 2019 pneumonia. *Medicine (Baltimore)*. 2020 Oct 16;99(42):e22433. doi: 10.1097/MD.00000000000022433 **(Q2, IF 1.44)**

Sarzi-Puttini P, Giorgi V, Marotto D, Atzeni F. Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. *Nat Rev Rheumatol*. 2020 Nov;16(11):645-660. doi: 10.1038/s41584-020-00506-w. Epub 2020 Oct 6 **(Q1, IF 18.54)**

Marotto D, Atzeni F, Ardizzone S, Monteleone G, Giorgi V, **Sarzi-Puttini P**. Extra-intestinal manifestations of inflammatory bowel diseases. *Pharmacol Res*. 2020 Sep 27:105206. doi: 10.1016/j.phrs.2020.105206. Online ahead of print **(Q1, IF 5.57)**

Salaffi F, Di Carlo M, Carotti M, Ceccarelli L, Farah S, Marotto D, Giorgi V, **Sarzi-Puttini P**. Predictive validity of the 5-item Compliance Questionnaire for Rheumatology (CQR5) in detecting poor adherence of patients with rheumatoid arthritis to biological medication. *Arthritis Res Ther*. 2020 Sep 29;22(1):227. doi: 10.1186/s13075-020-02319-4 **(Q1, IF 4.10)**

Alciati A, Cirillo M, Masala IF, **Sarzi-Puttini P**, Atzeni F. Differences in depression, anxiety and stress disorders between fibromyalgia associated with rheumatoid arthritis and primary fibromyalgia *Stress Health*. 2020 Sep 29. doi: 10.1002/smi.2992. Online ahead of print

Sarzi-Puttini P, Marotto D, Caporali R, Montecucco CM, Favalli EG, Franceschini F, Fredi M, Balduzzi S, Bazzani C, Bongiovanni S, Giorgi V, Batticciotto A, Cappelli A, Balzarini P, Dagna L, Sartorelli S, Ravagnani V, Tamanini S, Farah S, Faggioli P, Castelnovo L, Lurati AM, Galli M, Salaffi F. Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. *J Autoimmun*. 2020 Sep 22:102545. doi: 10.1016/j.jaut.2020.102545. Online ahead of print **(Q1, IF 7.61)**

Ditto MC, Parisi S, Varisco V, Talotta R, Batticciotto A, Antiville M, Gerardi MC, Agosti M, Borrelli R, Fusaro E, **Sarzi-Puttini P**. Prevalence of hepatitis B virus infection and risk of reactivation in rheumatic population undergoing biological therapy. *Clin Exp Rheumatol*. 2020 Sep 16. Online ahead of print **(Q1, IF 3.01)**

Salaffi F, Di Carlo M, Bazzichi L, Atzeni F, Govoni M, Biasi G, Di Franco M, Mozzani F, Gremese E, Dagna L, Batticciotto A, Fischetti F, Giacomelli R, Guiducci S, Guggino G, Bentivegna M, Gerli R, Salvarani C, Bajocchi G, Ghini M, Iannone F, Giorgi V, Farah S, Cirillo M, Bonazza S, Barbagli S, Gioia C, Santilli D, Capacci A, Cavalli G, Carubbi F, Nacci F, Riccucci I, Sinigaglia L, Masullo M, Polizzi BM, Cutolo M, **Sarzi-Puttini P**. Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients. *Rheumatology (Oxford)*. 2020 Aug 13:keaa355. doi: 10.1093/rheumatology/keaa355. Online ahead of print **(Q1, IF 5.60)**

Salaffi F, Di Carlo M, Farah S, Atzeni F, Buskila D, Ablin JN, Häuser W, **Sarzi-Puttini P**. Comment on: Diagnosis of fibromyalgia: comparison of the 2011/2016 ACR and APT criteria and validation of the modified Fibromyalgia Assessment Status: reply. *Rheumatology (Oxford)*. 2020 Oct 1;59(10):e81. doi: 10.1093/rheumatology/keaa340

Iannone F, Favalli EG, Caporali R, D'Angelo S, Cantatore FP, **Sarzi-Puttini P**, Foti R, Conti F, Carletto A, Gremese E, Cauli A, Ramonda R, Palermo A, Epis O, Priora M, Bergossi F, Frediani B, Salaffi F, Lopalco G, Cacchiapaglia F, Marchesoni A, Biggioggero M, Bugatti S, Balduzzi S, Carriero A, Corrado A, Bongiovanni S, Benenati A, Miranda F, Fracassi E, Perra D, Ferraccioli G, Lapadula G. Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. *Joint Bone Spine*. 2020 Aug 2:S1297-319X(20)30147-0. doi: 10.1016/j.jbspin.2020.07.011. Online ahead of print

Scirè CA, Carrara G, Zanetti A, Landolfi G, Chighizola C, Alunno A, Andreoli L, Caporali R, Gerli R, Sebastiani GD, Valesini G, Sinigaglia L; Italian Registry of the Italian Society of Rheumatology (CONTROL-19). COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19). *Clin Exp Rheumatol*. 2020 Jul-Aug;38(4): 748- 753. Epub 2020 Jul 28

Manara M, Caporali R, Lomater C, Gorla R, Fusaro E, **Sarzi-Puttni P**, Stobbione P, Capri S, Sinigaglia L. Impact of one-year treatment with biotechnological drugs on work ability in patients with rheumatoid arthritis in Italy: a prospective real-life study. *Clin Exp Rheumatol*. 2020 Jun 19. Online ahead of print

Marino F, D'Angelo S, Masala IF, Gerratana E, Nucera V, La Corte L, Giallanza M, **Sarzi-Puttni P**, Atzeni F. Toxicological considerations in the treatment of axial spondylo-arthritis. *Expert Opin Drug Metab Toxicol*. 2020 Aug;16(8):663-672. doi: .1080/17425255.2020.1783240. Epub 2020 Jun 27

Carotti M, Salaffi F, **Sarzi-Puttni P**, Agostini A, Borgheresi A, Minorati D, Galli M, Marotto D, Giovagnoni A. Chest CT features of coronavirus disease 2019 (COVID-19) pneumonia: key points for radiologists. *Radiol Med*. 2020 Jul;125(7):636-646. doi: 10.1007/s11547-020-01237-4. Epub 2020 Jun 4

of mixed cryoglobulinaemia syndrome and circulating cryoglobulins in a population-based survey: the Origgio study. *Autoimmun Rev*. 2014 Jun;13(6):609-14. doi: 10.1016/j.autrev.2013.11.005. Epub 2014 Jan 10. PMID: 24418294.

Infantino M, Bentow C, Seaman A, Benucci M, Atzeni F, **Sarzi-Puttni P**, Olivito B, Meacci F, Manfredi M, Mahler M. Highlights on novel technologies for the detection of antibodies to Ro60, Ro52, and SS-B. *Clin Dev Immunol*. 2013;2013:978202.

Cimmino MA, Scarpa R, Caporali R, Parazzini F, Zaninelli A, **Sarzi-Puttni P**. Body mass and osteoarthritic pain: results from a study in general practice. *Clin Exp Rheumatol*. 2013 Nov-Dec;31(6):843-9. (Q1, IF 3.01)

Benucci M, Saviola G, Meacci F, Manfredi M, Infantino M, Campi P, Severino M, Iorno M, **Sarzi-Puttni P**, Atzeni F. No Correlations Between the Development of Specific IgA and IgM Antibodies Against Anti-TNF Blocking Agents, Disease Activity and Adverse Side Reactions in Patients with Rheumatoid Arthritis. *Open Rheumatol J*. 2013 Sep 30;7:75-80.(Q3)

Atzeni F, **Sarzi-Puttni P**, Gianturco L, Turiel M. Reply: To PMID 22899452. (*Arthritis Care ResHoboken*). 2013 Dec;65(12):2063.

Scirè CA, Caporali R, **Sarzi-Puttni P**, Frediani B, Di Franco M, Tincani A, Sinigaglia L, Sfriso P, Tirri R, Bellis E, Delsante G, Porru G, Salaffi F, Giuggioli D, Rossini M, Todoerti M, Bazzichi L, Govoni M, Gerli R, Raschetti R, Minisola G, Montecucco C, Todesco S; MonitorNet project. Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database. *Clin Exp Rheumatol*. 2013 Nov-Dec;31(6):857-63. Epub 2013 Aug 26.

Iannone F, Gremese E, Gallo G, **Sarzi-Puttni P**, Botsios C, Trotta F, Gasperini S, Galeazzi M, Adams S, Cantin, Sebastiani M, Gorla R, Marchesoni A, Giardina A, Foti R, Mele A, Bruschi E, Bagnato G, Erre GL, Lapadula G; GISEA (Gruppo Italiano Studio Early Arthritis). High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register. *Clin Rheumatol*. 2014 Jan;33(1):31-7.

Atzeni F, Boiardi L, Salli S, Benucci M, **Sarzi-Puttni P**. Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis. *Expert Rev Clin Immunol*. 2013 Jul;9(7):649-57. doi: 10.1586/1744666X.2013.811173. PMID: 23899235.

Salaffi F, Franchignoni F, Giordano A, Ciapetti A, **Sarzi-Puttni P**, Ottonello M. Psychometric characteristics of the Italian version of the revised Fibromyalgia Impact Questionnaire using classical test theory and Rasch analysis. *Clin Exp Rheumatol*. 2013 Nov-Dec;31(6 Suppl 79):S41-9. Epub 2013 Jun 26. (Q1, IF 3.01)

Atzeni F, **Sarzi-Puttni P**, Mutti A, Bugatti S, Cavagna L, Caporali R. Long-term safety of abatacept in patients with rheumatoid arthritis. *Autoimmun Rev*. 2013 Oct;12(12):1115-7. doi: 10.1016/j.autrev.2013.06.011. Epub 2013 Jun 22. PMID: 23800448.

Caporali R, Bugatti S, Cavagna L, Antivalle M, **Sarzi-Puttni P**. Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: could it be the first step of the treatment? *Autoimmun Rev*. 2014 Jan;13(1):49-53. doi: 10.1016/j.autrev.2013.06.008. Epub

Cassinotti A, **Sarzi-Puttni P**, Fichera M, Shoenfeld Y, de Franchis R, Ardizzone S. Immunity, autoimmunity and inflammatory bowel disease. *Autoimmun Rev*. 2014 Jan;13(1):1-2. doi: 10.1016/j.autrev.2013.06.007. Epub 2013 Jun 15. PMID: 23777820.

Atzeni F, Defendenti C, Ditto MC, Batticciotto A, Ventura D, Antivalle M, Ardizzone S, **Sarzi-Puttni P**. Rheumatic manifestations in inflammatory bowel disease. *Autoimmun Rev*. 2014 Jan;13(1):20-3. doi: 10.1016/j.autrev.2013.06.006. Epub 2013 Jun 15. PMID: 23774109

Talotta R, Bagnato GL, Atzeni F, Ditto MC, Bitto A, Squadrito F, Lo Gullo A, **Sarzi-Puttni P**, Bagnato GF. Polymorphic alleles in exon 1 of the CTLA4 gene do not predict the response to abatacept. *Clin Exp Rheumatol*. 2013 Sep-Oct;31(5):813. Epub 2013 May 28.

Atzeni F, Bongiovanni S, Marchesoni A, Filippini M, Caporali R, Gorla R, Cavagna L, Favalli EG, Saccardo F, **Sarzi-Puttni P**. Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28 scores. *Joint Bone Spine*. 2014 Jan;81(1):37-40. (Q2, IF 3.27)

Sarzi-Puttni P, Atzeni F, Lanata L, Bagnasco M. Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis. *Clin Exp Rheumatol*. 2013 Sep-Oct;31(5):731-8. Epub 2013 May 17. PMID: 23711416.

Mathews RJ, Robinson JL, Battellino M, Wong C, Taylor JC; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), Eyre S, Churchman SM, Wilson AG, Isaacs JD, Hyrich K, Barton A, Plant D, Savic S, Cook GP, **Sarzi-Puttni P**, Emery P, Barrett JH, Morgan AW, McDermott MF. Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. *Ann Rheum Dis*. 2014 Jun;73(6):1202-10. (Q1, IF 16.02)

Benucci M, Saviola G, Manfredi M, **Sarzi-Puttni P**, Atzeni F. Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis. *Biologics*. 2013;7:69-75.

Quartuccio L, Fabris M, Pontarini E, Salvin S, Zabotti A, Benucci M, Manfredi M, Biasi D, Ravagnani V, Atzeni F, **Sarzi-Puttini P**, Morassi P, Fischetti F, Tomietto P, Bazzichi L, Saracco M, Pellerito R, Cimmino M, Schiavon F, Carraro V, Semeraro A, Caporali R, Cavagna L, Bortolotti R, Paolazzi G, Govoni M, Bombardieri S, De Vita S. The 158VV Fcγ receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. *Ann Rheum Dis*. 2014 Apr;73(4):716-21.

Defendenti C, Atzeni F, Croce AM, Mussani E, Saibeni S, Bollani S, Grosso S, Almasio PL, Bruno S, **Sarzi-Puttini P**. Morphological distribution of μ chains and cd15 receptors in colorectal polyp and adenocarcinoma specimens. *BMC Clin Pathol*. 2013 Mar 1;13:8. **(Q2; IF 1.23)**

Atzeni F, Benucci M, **Sarzi-Puttini P**. Infections during treatment with biological agents and possible treatment in clinical practice. *Expert Rev Clin Immunol*. 2013 Mar;9(3):193-5. doi: 10.1586/eci.13.3. PMID: 23445193.

Sarzi-Puttini P, Atzeni F, Di Franco M, Buskila D, Alciati A, Giacomelli C, Rossi A, Bazzichi L. Dysfunctional syndromes and fibromyalgia: a 2012 critical digest. *Clin Exp Rheumatol*. 2012 Nov-Dec;30(6 Suppl 74):143-51. Epub 2012 Dec 17. PMID: 23261014.

Alciati A, **Sarzi-Puttini P**, Batticciotto A, Torta R, Gesuele F, Atzeni F, Angst J. Overactive lifestyle in patients with fibromyalgia as a core feature of bipolar spectrum disorder. *Clin Exp Rheumatol*. 2012 Nov-Dec;30(6 Suppl 74):122-8.

Iannuccelli C, Mannocci F, Guzzo MP, Olivieri M, Gerardi MC, Atzeni F, **Sarzi-Puttini P**, Valesini G, Di Franco M. Complementary treatment in fibromyalgia: combination of somatic and abdominal acupuncture. *Clin Exp Rheumatol*. 2012 Nov-Dec;30(6 Suppl 74):112-6.

Labianca R, **Sarzi-Puttini P**, Zuccaro SM, Cherubino P, Vellucci R, Fornasari D. Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain. *Clin Drug Investig*. 2012 Feb;32 Suppl 1:53-63

Cherubino P, **Sarzi-Puttini P**, Zuccaro SM, Labianca R. The management of chronic pain in important patient subgroups. *Clin Drug Investig*. 2012 Feb;32 Suppl 1:35-44. doi: 10.2165/11630060-000000000-00000. PMID: 23389874.

Sarzi-Puttini P, Vellucci R, Zuccaro SM, Cherubino P, Labianca R, Fornasari D. The appropriate treatment of chronic pain. *Clin Drug Investig*. 2012 Feb;32 Suppl 1:21-33. doi: 10.2165/11630050-000000000-00000. PMID: 23389873.

Zuccaro SM, Vellucci R, **Sarzi-Puttini P**, Cherubino P, Labianca R, Fornasari D. Barriers to pain management : focus on opioid therapy. *Clin Drug Investig*. 2012 Feb;32 Suppl 1:11-9. doi: 10.2165/11630040-000000000-00000. PMID: 23389872.

Benucci M, Manfredi M, Saviola G, **Sarzi-Puttini P**, Atzeni F. Changes in atherosclerosis markers during tocilizumab treatment in rheumatoid arthritis: preliminary results. *Clin Exp Rheumatol*. 2013 Mar-Apr;31(2):322-3.

Atzeni F, Benucci M, Salli S, Bongiovanni S, Boccassini L, **Sarzi-Puttini P**. Different effects of biological drugs in rheumatoid arthritis. *Autoimmun Rev*. 2013 Mar;12(5):575-9. doi: 10.1016/j.autrev.2012.10.020. Epub 2012 Dec 3. PMID: 23219774.

Atzeni F, Talotta R, Salaffi F, Cassinotti A, Varisco V, Battellino M, Ardizzone S, Pace F, **Sarzi-Puttini P**. Immunogenicity and autoimmunity during anti-TNF therapy. *Autoimmun Rev*. 2013 May;12(7):703-8. doi: 10.1016/j.autrev.2012.10.021. Epub 2012 Nov 30. PMID: 23207283.

Salaffi F, **Sarzi-Puttini P**. Old and new criteria for the classification and diagnosis of fibromyalgia: comparison and evaluation. *Clin Exp Rheumatol*. 2012 Nov-Dec;30(6 Suppl 74):3-9. Epub 2012 Dec 14. PMID: 23137811.

Häuser W, **Sarzi-Puttini P**, Tölle TR, Wolfe F. Placebo and nocebo responses in randomised controlled trials of drugs applying for approval for fibromyalgia syndrome treatment: systematic review and meta-analysis. *Clin Exp Rheumatol*. 2012 Nov-Dec;30(6 Suppl 74):78-87. Epub 2012 Dec 14. PMID: 23137770.

Castelli L, Tesio V, Colonna F, Molinaro S, Leombruni P, Bruzzone M, Fusaro E, **Sarzi-Puttini P**, Torta R. Alexithymia and psychological distress in fibromyalgia: prevalence and relation with quality of life. *Clin Exp Rheumatol*. 2012 Nov-Dec;30(6 Suppl 74):70-7.

Mader R, Buskila D, Verlaan JJ, Atzeni F, Olivieri I, Pappone N, Di Girolamo C, **Sarzi-Puttini P**. Developing new classification criteria for diffuse idiopathic skeletal hyperostosis: back to square one. *Rheumatology (Oxford)*. 2013 Feb;52(2):326-30. **(Q1, IF 5.60)**

Fabris M, Quartuccio L, Vital E, Pontarini E, Salvin S, Fabro C, Zabotti A, Benucci M, Manfredi M, Ravagnani V, Biasi D, Atzeni F, **Sarzi-Puttini P**, Morassi P, Fischetti F, Bazzicchi L, Saracco M, Pellerito R, Cimmino M, Carraro V, Semeraro A, Schiavon F, Caporali R, Bortolotti R, Govoni M, Fogolari F, Tonutti E, Bombardieri S, Emery P, De Vita S. The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers. *Arthritis Rheum*. 2013 Jan;65(1):88-97.

Benucci M, Saviola G, Manfredi M, **Sarzi-Puttini P**, Atzeni F. Tumor necrosis factors blocking agents: analogies and differences. *Acta Biomed*. 2012 Apr;83(1):72-80. PMID: 22978063.

Atzeni F, Boiardi L, Casali B, Farnetti E, Nicoli D, **Sarzi-Puttini P**, Pipitone N, Olivieri I, Cantini F, Salvi F, La Corte R, Triolo G, Filippini D, Paolazzi G, Salvarani C. CC chemokine receptor 5 polymorphism in Italian patients with Behcet's disease. *Rheumatology (Oxford)*. 2012 Dec;51(12):2141-5.

Turiel M, Gianturco L, Ricci C, **Sarzi-Puttini P**, Tomasoni L, Colonna V, Ferrario P, Epis O, Atzeni F. Silent cardiovascular involvement in patients with diffuse systemic sclerosis: a controlled cross-sectional study. *Arthritis CareRes (Hoboken)*. 2013 Feb;65(2):274-80.

Ferraccioli G, Tolusso B, Bobbio-Pallavicini F, Gremese E, Ravagnani V, Benucci M, Podestà E, Atzeni F, Mannocci A, Biasi D, Manfredi M, **Sarzi-Puttini P**, Laganà B, Montecucco C. Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis. *PLoS One*. 2012;7(7):e40362. doi: 10.1371/journal.pone.0040362. Epub 2012 Jul 30. PMID: 22859946; PMCID: PMC3408482.

- Batticciotto A, Atzeni F, Foglia S, Antivalle M, Serafin A, **Sarzi-Puttini P**. Feet nailfold capillaroscopy is not useful to detect the typical scleroderma pattern. *Clin Exp Rheumatol*. 2012 Mar-Apr;30(2 Suppl 71):S116-7. Epub 2012 May 30. PMID: 22691219.
- Atzeni F, **Sarzi-Puttini P**, Botsios C, Carletto A, Cipriani P, Favalli EG, Frati E, Foschi V, Gasparini S, Giardina A, Gremese E, Iannone F, Sebastiani M, Ziglioli T, Biasi D, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Gorla R, Govoni M, Lapadula G, Marchesoni A, Salaffi F, Punzi L, Triolo G, Ferraccioli G. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. *Autoimmun Rev*. 2012 Dec;12(2):225-9. doi: 10.1016/j.autrev.2012.06.008. Epub 2012 Jul 13. PMID: 22796281.
- Atzeni F, Ventura D, Batticciotto A, Boccassini L, **Sarzi Puttini P**. Interleukin 6 Blockade: Tocilizumab in Psoriatic Arthritis. *J Rheumatology* 2012 Suppl. , 39, 97-99, ISSN: 0315-162X, doi: 10.3899/jrheum.120256
- Defendenti C, Grosso S, Atzeni F, Croce A, Senesi O, Saibeni S, Bollani S, Almasio PL, Bruno S, **Sarzi-Puttini P**. Unusual B cell morphology in inflammatory bowel disease. *Pathol Res Pract*. 2012 Jul 15;208(7):387-91. doi: 10.1016/j.prp.2012.05.003. Epub 2012
- Benucci M, Saviola G, Baiardi P, Manfredi M, **Sarzi Puttini P**, Atzeni F. Determinants of Risk Infection During Therapy with Anti TNF-Alpha Blocking Agents in Rheumatoid Arthritis. *Open Rheumatol J*. 2012;6:33-7. doi: 10.2174/1874312901206010033. Epub 2012 Apr 24. PMID: 22655000; PMCID: PMC3362853.
- Iannone F, Gremese E, Atzeni F, Biasi D, Botsios C, Cipriani P, Ferri C, Foschi V, Galeazzi M, Gerli R, Giardina A, Marchesoni A, Salaffi F, Ziglioli T, Lapadula G; Gruppo Italiano di Studio sulle Early Arthritides (GISEA) (Coinvestigator: **Sarzi-Puttini P**) Longterm retention of tumor necrosis factor- α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. *J Rheumatol*. 2012 Jun;39(6):1179-84. doi: 10.3899/jrheum.111125. Epub 2012 Apr 1. PMID: 22467933.
- Cassisi G, **Sarzi-Puttini P**, Cazzola M. Chronic widespread pain and fibromyalgia: could there be some relationships with infections and vaccinations? *Clin Exp Rheumatol*. 2011 Nov-Dec;29(6 Suppl 69):S118-26. Epub 2012 Jan 3. PMID: 22243559.
- Di Franco M, Iannuccelli C, Bazzichi L, Atzeni F, Consensi A, Salaffi F, Pietropaolo M, Alessandri C, Basili S, Olivieri M, Bombardieri S, Valesini G, **Sarzi-Puttini P**. Misdiagnosis in fibromyalgia: a multicentre study. *Clin Exp Rheumatol*. 2011 Nov-Dec;29(6 Suppl 69):S104-8. Epub 2012 Jan 3. PMID: 22243557.
- Bazzichi L, Sernissi F, Consensi A, Giacomelli C, **Sarzi-Puttini P**. Fibromyalgia: a critical digest of the recent literature. *Clin Exp Rheumatol*. 2011 Nov-Dec;29(6 Suppl 69):S1-11. Epub 2012 Jan 9. PMID: 22243549.
- Atzeni F, Sarzi-Puttini P. Rheumatoid arthritis: Why wait? Explaining delays in seeking therapy for early arthritis. *Nat Rev Rheumatol*. 2012 Mar 6;8(4):190-1. doi: 10.1038/nrrheum.2012.24. PMID: 22391519.
- Atzeni F, **Sarzi-Puttini P**. Twelve years' experience with etanercept in the treatment of rheumatoid arthritis: how it has changed clinical practice. *Expert Rev Clin Immunol*. 2012 Mar;8(3):213-22. doi: 10.1586/eci.12.6. PMID: 22390484.
- Casale R, Damiani C, Rosati V, Atzeni F, **Sarzi-Puttini P**, Nica AS. Efficacy of a comprehensive rehabilitation programme combined with pharmacological treatment in reducing pain in a group of OA patients on a waiting list for total joint replacement. *Clin Exp Rheumatol*. 2012 Mar-Apr;30(2):233-9. Epub 2012 Apr 13. PMID: 22341040.
- Marchesoni A, Atzeni F, Spadaro A, Lubrano E, Provenzano G, Cauli A, Olivieri I, Melchiorre D, Salvarani C, Scarpa R, **Sarzi-Puttini P**, Montepaone M, Porru G, D'Angelo S, Catano M, Costa L, Manara M, Varisco V, Rotunno L, DE Lucia O, DE Marco G. Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia. *J Rheumatol*. 2012 Apr;39(4):849-55. doi: 10.3899/jrheum.110893. Epub 2012 Jan 15. PMID: 22247363.
- Defendenti C, **Sarzi-Puttini P**, Grosso S, Croce A, Senesi O, Saibeni S, Bollani S, Almasio PL, Bruno S, Atzeni F. B lymphocyte intestinal homing in inflammatory bowel disease. *BMC Immunol*. 2011 Dec 30;12:71. doi: 10.1186/1471-2172-12-71. PMID: 22208453; PMCID: PMC3261110.
- Benucci M, Saviola G, Manfredi M, **Sarzi-Puttini P**, Atzeni F. Cost effectiveness analysis of disease-modifying antirheumatic drugs in rheumatoid arthritis. A systematic review literature. *Int J Rheumatol*. 2011;2011:845496. doi: 10.1155/2011/845496. Epub 2011 Nov 22. PMID: 22162693; PMCID: PMC3228304.
- Fabris M, De Vita S, Pasini E, Quartuccio L, Pontarini E, Lombardi S, Fabro C, **Sarzi-Puttini P**, Pellerito R, Benucci M, Morassi P, Biasi D, Curcio F, Dolcetti R. Chlamydomydia psittaci subclinical infection in chronic polyarthritis. *Clin Exp Rheumatol*. 2011 Nov-Dec;29(6):977-82. Epub 2011 Dec 22. PMID: 22153301.
- Stoenoiu MS, Aydin S, Tektonidou M, Ravelingien I, le Guern V, Fiehn C, Remy P, Delahousse M, Petera P, Quémeneur T, Vasconcelos C, D'Cruz D, Gilboe IM, Jadoul M, Karras A, Depresseux G, Guillevin L, Cervera R, Cosyns JP, Houssiau FA; MAINTAIN Nephritis (Co-investigator: **Sarzi-Puttini P**) Trial Group. Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial. *Nephrol Dial Transplant*. 2012 May;27(5):1924-30. Epub 2011 Nov 22. PubMed PMID: 22110048
- Sarzi-Puttini P**, Atzeni F, Salaffi F, Cazzola M, Benucci M, Mease PJ. Multidisciplinary approach to fibromyalgia: what is the teaching? *Best Pract Res Clin Rheumatol*. 2011 Apr;25(2):311-9. Review. PubMed PMID: 22094204.
- Mease PJ, Dundon K, **Sarzi-Puttini P**. Pharmacotherapy of fibromyalgia. *Best Pract Res Clin Rheumatol*. 2011 Apr;25(2):285-97. Review. PubMed PMID: 22094202.
- Salaffi F, **Sarzi-Puttini P**, Ciapetti A, Atzeni F. Clinimetric evaluations of patients with chronic widespread pain. *Best Pract Res Clin Rheumatol*. 2011 Apr;25(2):249-70. Review. PubMed PMID: 22094200.
- Spaeth M, Rizzi M, **Sarzi-Puttini P**. Fibromyalgia and sleep. *Best Pract Res Clin Rheumatol*. 2011 Apr;25(2):227-39. Review. PubMed PMID: 22094198.
- Atzeni F, Cazzola M, Benucci M, Di Franco M, Salaffi F, **Sarzi-Puttini P**. Chronic widespread pain in the spectrum of rheumatological diseases. *Best Pract Res Clin Rheumatol*. 2011 Apr;25(2):165-71. Review. PubMed PMID: 22094193.

- Aarzi-Puttini P**, Atzeni F, Mease PJ. Chronic widespread pain: from peripheral to central evolution. *Best Pract Res Clin Rheumatol*. 2011 Apr;25(2):133-9. Review. PubMed PMID: 22094190.
- Sarzi-Puttini P**, Atzeni F, Mease P. Chronic widespread pain or fibromyalgia? That is the question. *Best Pract Res Clin Rheumatol*. 2011 Apr;25(2):131-2. PubMed PMID: 22094189.
- Doria A, Putterman C, **Sarzi-Puttini P**, Szekanecz Z, Shoenfeld Y. Controversies in rheumatism and autoimmunity. *Autoimmun Rev*. 2012 Jun;11(8):555-7. Epub 2011 Oct 25. PubMed PMID: 22056979.
- Turiel M, **Sarzi-Puttini P**, Atzeni F, De Gennaro Colonna V, Gianturco L, Tomasoni L. Cardiovascular injury in systemic autoimmune diseases: an update. *Intern Emerg Med*. 2011 Oct;6 Suppl 1:99-102. PubMed PMID: 22009619.
- Atzeni F, Boiardi L, Nicoli D, Farnetti E, Casali B, **Sarzi-Puttini P**, Pipitone N, Olivieri I, Cantini F, Salvi F, La Corte R, Triolo G, Filippini D, Paolazzi G, Salvarani C. PLA1/A2 polymorphism of the platelet glycoprotein receptors IIIa in Behçet's disease. *Clin Exp Rheumatol*. 2011 Jul-Aug;29(4 Suppl 67):S38-43. Epub 2011 Sep 27. PubMed PMID: 21813062.
- Olivieri I, **Sarzi-Puttini P**, Bugatti S, Atzeni F, d'Angelo S, Caporali R. Early treatment in early undifferentiated arthritis. *Autoimmun Rev*. 2012 Jun;11(8):589-92. Epub 2011 Oct 20. Review. PubMed PMID: 22037115.
- Ablin JN, Buskila D, Van Houdenhove B, Luyten P, Atzeni F, **Sarzi-Puttini P**. Is fibromyalgia a discrete entity? *Autoimmun Rev*. 2012 Jun;11(8):585-8. Epub 2011 Oct 22. Review. PubMed PMID: 22036826.
- Iannuccelli C, **Sarzi-Puttini P**, Atzeni F, Cazzola M, di Franco M, Guzzo MP, Bazzichi L, Cassisi GA, Marsico A, Stisi S, Salaffi F. Psychometric properties of the Fibromyalgia Assessment Status (FAS) index: a national web-based study of fibromyalgia. *Clin Exp Rheumatol*. 2011 Nov-Dec;29(6 Suppl 69):S49-54. Epub 2012 Jan 3. PubMed PMID: 22011656.
- Caporali R, Conti F, Alivernini S, Atzeni F, Seriole B, Cutolo M, Valesini G, Ferraccioli G, **Sarzi-Puttini P**, Salvarani C, Guiducci S, Zampogna G, Gremese E, Pipitone N, Scrivo R, Bugatti S, Montecucco C, Matucci-Cerinic M; Italian Society for Rheumatology. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. *Clin Exp Rheumatol*. 2011 May-Jun;29(3 Suppl 66):S7-14. Epub 2011 Jul 26. Review. PubMed PMID: 21906423.
- Covelli M, Lanciano E, Tartaglia P, Grattagliano V, Angelelli G, Atzeni F, **Sarzi-Puttini P**, Lapadula G. Rituximab treatment for Sjogren syndrome-associated non-Hodgkin's lymphoma: case series. *Rheumatol Int*. 2012 Oct;32(10):3281-4. Epub 2011 Jul 30. PubMed PMID: 21805176.
- Mease PJ, Clauw DJ, Christensen R, Crofford LJ, Gendreau RM, Martin SA, Simon LS, Strand V, Williams DA, Arnold LM; (Co-investigator: **P Sarzi-Puttini**) OMERACT Fibromyalgia Working Group. Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update. *J Rheumatol*. 2011 Jul;38(7):1487-95. PubMed PMID: 21724721; PubMed Central PMCID: PMC3426365.
- Alciati A, Gesuele F, Rizzi A, **Sarzi-Puttini P**, Foschi D. Childhood parental loss and bipolar spectrum in obese bariatric surgery candidates. *Int J Psychiatry Med*. 2011;41(2):155-71. PubMed PMID: 21675347.
- Atzeni F, **Sarzi-Puttini P**, Sitia S, Tomasoni L, Gianturco L, Battellino M, Boccassini L, De Gennaro Colonna V, Marchesoni A, Turiel M. Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis. *J Rheumatol*. 2011 Aug;38(8):1661-4. Epub 2011 Jun 1. PubMed PMID: 21632673.
- Benucci M, Saviola G, Baiardi P, Manfredi M, **Sarzi-Puttini P**, Atzeni F. Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis. *Int J Immunopathol Pharmacol*. 2011 Jan-Mar;24(1):269-74. PubMed PMID: 21496415.
- Branco JC, Cherin P, Montagne A, Bouroubi A; Multinational Coordinator Study Group. (Co-investigator: **Sarzi-Puttini P**) Longterm therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study. *J Rheumatol*. 2011 Jul;38(7):1403-12. Epub 2011 Apr 1. PubMed PMID: 21459941.
- Sitia S, Tomasoni L, Cicala S, Atzeni F, Ricci C, Gaeta M, **Sarzi-Puttini P**, Turiel M. Detection of preclinical impairment of myocardial function in rheumatoid arthritis patients with short disease duration by speckle tracking echocardiography. *Int J Cardiol*. 2012 Sep 20;160(1):8-14. doi: 10.1016/j.ijcard.2011.03.012. Epub 2011 Mar 29. PubMed PMID: 21450355.
- Cazzola M, Atzeni F, Salaffi F, Stisi S, Cassisi G, **Sarzi-Puttini P**. Which kind of exercise is best in fibromyalgia therapeutic programmes? A practical review. *Clin Exp Rheumatol*. 2010 Nov-Dec;28(6 Suppl 63):S117-24. Epub 2010 Dec 22. Review. PubMed PMID: 21176431.
- Di Franco M, Iannuccelli C, Atzeni F, Cazzola M, Salaffi F, Valesini G, **Sarzi-Puttini P**. Pharmacological treatment of fibromyalgia. *Clin Exp Rheumatol*. 2010 Nov-Dec;28(6 Suppl 63):S110-6. Epub 2010 Dec 22. Review. PubMed PMID: 21176430.
- Crawford BK, Piau EC, Lai C, **Sarzi-Puttini P**. Assessing sleep in fibromyalgia: investigation of an alternative scoring method for the Jenkins Sleep Scale based on data from randomized controlled studies. *Clin Exp Rheumatol*. 2010 Nov-Dec;28(6 Suppl 63):S100-9. Epub 2010 Dec 22. PubMed PMID: 21176429.
- Ditto MC, Antivalle M, Badini M, Battellino M, Cogliati C, **Sarzi-Puttini P**. Is it antiphospholipid syndrome? *Int J Rheumatol*. 2010;2010:932157. Epub 2011 Jan 13. PubMed PMID: 21318137; PubMed Central PMCID: PMC3034954.
- Pietrogrande M, De Vita S, Zignego AL, Pioltelli P, Sansonno D, Sollima S, Atzeni F, Saccardo F, Quartuccio L, Bruno S, Bruno R, Campanini M, Candela M, Castelnovo

L, Gabrielli A, Gaeta GB, Marson P, Mascia MT, Mazzaro C, Mazzotta F, Meroni P, Montecucco C, Ossi E, Piccinino F, Prati D, Puoti M, Riboldi P, Riva A, Roccatello D, Sagnelli E, Scaini P, Scarpato S, Sinico R, Taliani G, Tavoni A, Bonacci E, Renoldi P, Filippini D, **Sarzi-Puttni P**, Ferri C, Monti G, Galli M. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. *Autoimmun Rev.* 2011 Jun;10(8):444-54. Epub 2011 Feb 15. Review. PubMed PMID: 21303705

Defendenti C, Guercilena G, Freschi A, Croce AM, Servida F, Russo S, Grosso S, Longo M, Spina MF, Miadonna A, Atzeni F, **Sarzi-Puttni P**. [Serological and clinical aspects in initial Wegener's disease. A case report]. *Recenti Prog Med.* 2010 Sep;101(9):349-54. Italian. PubMed PMID: 21268372.

Atzeni F, **Sarzi-Puttni P**, Gorla R, Marchesoni A, Caporali R. Switching rheumatoid arthritis treatments: an update. *Autoimmun Rev.* 2011 May;10(7):397-403. Epub 2011 Jan 22. Review. PubMed PMID: 21262393.

Atzeni F, Leccese P, D'Angelo S, **Sarzi-Puttni P**, Olivieri I. Successful treatment of leg ulcers in Behçet's disease using adalimumab plus methotrexate after the failure of infliximab. *Clin Exp Rheumatol.* 2010 Jul-Aug;28(4 Suppl 60):S94. Epub 2010 Sep 24. PubMed PMID: 20868581.

Ablin JN, Cohen H, Clauw DJ, Shalev R, Ablin E, Neumann L, **Sarzi-Puttni P**, Buskila D. A tale of two cities - the effect of low intensity conflict on prevalence and characteristics of musculoskeletal pain and somatic symptoms associated with chronic stress. *Clin Exp Rheumatol.* 2010 Nov-Dec;28(6 Suppl 63):S15-21. Epub 2010 Dec 22. PubMed PMID: 21122267.

Fabris M, Quartuccio L, Lombardi S, Saracco M, Atzeni F, Carletto A, Cimmino M, Fabro C, Pontarini E, Pellerito R, Bambara LM, **Sarzi-Puttni P**, Cutolo M, Manfredi M, Benucci M, Morassi P, Fischetti F, Padovan M, Govoni M, Curcio F, Tonutti E, De Vita S. The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. *Autoimmun Rev.* 2012 Mar;11(5):315-20. Epub 2010 Oct 23. PubMed PMID: 20974296.

Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, Hessey E, Chen A, Tyrrell H, Shaw TM; IMAGE Investigators. (P. **Sarzi-Puttni**). Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. *Ann Rheum Dis.* 2011 Jan;70(1):39-46. Epub 2010 Oct 11. PubMed PMID: 20937671.

Defendenti C, Atzeni F, Spina MF, Grosso S, Cereda A, Guercilena G, Bollani S, Saibeni S, **Sarzi-Puttni PS**. Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. *Autoimmun Rev.* 2011 Jan;10(3):150-4. Epub 2010 Sep 18. Review. Erratum in: *Autoimmun Rev.* 2012 Jul;11(9):685. PubMed PMID: 20854935.

Atzeni F, Boccassini L, Antiville M, Salaffi F, **Sarzi-Puttni P**. Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study. *Ann Rheum Dis.* 2011 Apr;70(4):712-4. Epub 2010 Aug 31. PubMed PMID: 20810394.

Atzeni F, Turiel M, Hollan I, Meroni P, Sitia S, Tomasoni L, **Sarzi-Puttni P**. Usefulness of cardiovascular biomarkers and cardiac imaging in systemic rheumatic diseases. *Autoimmun Rev.* 2010 Oct;9(12):845-8. Epub 2010 Aug 6. Review. PubMed PMID: 20692380.

Sarzi-Puttni P, Atzeni F, Gerli R, Bartoloni E, Doria A, Barskova T, Matucci-Cerinic M, Sitia S, Tomasoni L, Turiel M. Cardiac involvement in systemic rheumatic diseases: An update. *Autoimmun Rev.* 2010 Oct;9(12):849-52. Epub 2010 Aug 6. Review. PubMed PMID: 20692379.

Sitia S, Tomasoni L, Atzeni F, Ambrosio G, Cordiano C, Catapano A, Tramontana S, Perticone F, Naccarato P, Camici P, Picano E, Cortigiani L, Bevilacqua M, Milazzo L, Cusi D, Barlassina C, **Sarzi-Puttni P**, Turiel M. From endothelial dysfunction to atherosclerosis. *Autoimmun Rev.* 2010 Oct;9(12):830-4. Epub 2010 Jul 30. Review. PubMed PMID: 20678595.

Atzeni F, Turiel M, Caporali R, Cavagna L, Tomasoni L, Sitia S, **Sarzi-Puttni P**. The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. *Autoimmun Rev.* 2010 Oct;9(12):835-9. Epub 2010 Jul 30. PubMed PMID: 20678592.

Benucci M, Manfredi M, **Sarzi-Puttni P**, Atzeni F. Predictive factors of response to rituximab therapy in rheumatoid arthritis: What do we know today? *Autoimmun Rev.* 2010 Oct;9(12):801-3. Epub 2010 Jul 23. Review. PubMed PMID: 20656069.

Caporali R, Bobbio-Pallavicini F, Atzeni F, Sakellariou G, Caprioli M, Montecucco C, **Sarzi-Puttni P**. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. *Arthritis Care Res (Hoboken).* 2010 Jun;62(6):749-54. PubMed PMID: 20535784.

Bassi N, Ghirardello A, Blank M, Zampieri S, **Sarzi-Puttni P**, Mantovani A, Shoenfeld Y, Doria A. IgG anti-pentraxin 3 antibodies in systemic lupus erythematosus. *Ann Rheum Dis.* 2010 Sep;69(9):1704-10. Epub 2010 May 3. PubMed PMID: 20439287.

Atzeni F, Straub RH, Cutolo M, **Sarzi-Puttni P**. Anti-TNF therapy restores the hypothalamic-pituitary-adrenal axis. *Ann N Y Acad Sci.* 2010 Apr;1193:179-81. Review. PubMed PMID: 20398027.

Atzeni F, Straub RH, Cutolo M, **Sarzi-Puttni P**. Psoriatic arthritis: clinical improvement and correlation with hormone axes in etanercept-treated patients. *Ann N Y Acad Sci.* 2010 Apr;1193:176-8. Review. PubMed PMID: 20398026.

Sarzi-Puttni P, Atzeni F, Cazzola M. Neuroendocrine therapy of fibromyalgia syndrome: an update. *Ann N Y Acad Sci.* 2010 Apr;1193:91-7. Review. PubMed PMID: 20398013.

Defendenti C, Spina MF, Grosso S, Longo M, Bollani S, Cereda A, Saibeni S, Guercilena G, Atzeni F, **Sarzi-Puttni P**. [Frequency and clinical associations of antineutrophil cytoplasmic antibodies. A regional experience]. *Recenti Prog Med.* 2010 Jan;101(1):16-26. Italian. PubMed PMID: 20391682.

Turiel M, Tomasoni L, Sitia S, Cicala S, Gianturco L, Ricci C, Atzeni F, De Gennaro Colonna V, Longhi M, **Sarzi-Puttni P**. Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis. *Cardiovasc Ther.* 2010 Oct;28(5):e53-64. doi: 10.1111/j.1755-5922.2009.00119.x. PubMed PMID: 20337633.

Salaffi F, **Sarzi-Puttini P**, Ciapetti A, Atzeni F. Assessment instruments for patients with fibromyalgia: properties, applications and interpretation. *Clin Exp Rheumatol*. 2009 Sep-Oct;27(5 Suppl 56):S92-105. Review. PubMed PMID: 20074447.

Buskila D, Ablin JN, Ben-Zion I, Muntanu D, Shalev A, **Sarzi-Puttini P**, Cohen H. A painful train of events: increased prevalence of fibromyalgia in survivors of a major train crash. *Clin Exp Rheumatol*. 2009 Sep-Oct;27(5 Suppl 56):S79-85. PubMed PMID: 20074445.

Salaffi F, **Sarzi-Puttini P**, Girolimetti R, Atzeni F, Gasparini S, Grassi W. Health-related quality of life in fibromyalgia patients: a comparison with rheumatoid arthritis patients and the general population using the SF-36 health survey. *Clin Exp Rheumatol*. 2009 Sep-Oct;27(5 Suppl 56):S67-74. PubMed PMID: 20074443.

Mease P, Buskila D, **Sarzi-Puttini P**. The fibromyalgia conundrum. *Clin Exp Rheumatol*. 2009 Sep-Oct;27(5 Suppl 56):S2-4. PubMed PMID: 20074432.

Caporali R, **Sarzi-Puttini P**, Atzeni F, Gorla R, Filippini M, Marchesoni A, Favalli EG, Bobbio-Pallavicini F, Montecucco C. Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry. *Autoimmun Rev*. 2010 Apr;9(6):465-9. Epub 2009 Dec 31. PubMed PMID: 20044040.

Turiel M, Sitia S, Atzeni F, Tomasoni L, Gianturco L, Giuffrida M, De Gennaro Colonna V, **Sarzi-Puttini P**. The heart in rheumatoid arthritis. *Autoimmun Rev*. 2010 Apr;9(6):414-8. Epub 2009 Nov 12. Review. PubMed PMID: 19913641

Atzeni F, **Sarzi-Puttini P**. Anti-cytokine antibodies for rheumatic diseases. *Curr Opin Investig Drugs*. 2009 Nov;10(11):1204-11. Review. PubMed PMID: 19876788.

Quartuccio L, Fabris M, Salvin S, Atzeni F, Saracco M, Benucci M, Cimmino M, Morassi P, Masolini P, Pellerito R, Cutolo M, **Puttini PS**, De Vita S. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. *Rheumatology (Oxford)*. 2009 Dec;48(12):1557-9. Epub 2009 Sep 29. PubMed PMID: 19789202.

Mader R, **Sarzi-Puttini P**, Atzeni F, Olivieri I, Pappone N, Verlaan JJ, Buskila D. Extraspinal manifestations of diffuse idiopathic skeletal hyperostosis. *Rheumatology (Oxford)*. 2009 Dec;48(12):1478-81. Epub 2009 Sep 25. Review. PubMed PMID: 19783587.

Defendenti C, Bollani S, Spina MF, Croce AM, Guercilena G, Saibeni S, Atzeni F, Saudelli M, Bruno S, Gherardi G, **Puttini PS**. [Anti-PR3 positive inflammatory bowel disease. Description of a case]. *Recenti Prog Med*. 2009 May;100(5):253-6. Italian. PubMed PMID: 19772216.

Marchesoni A, Zaccara E, Gorla R, Bazzani C, **Sarzi-Puttini P**, Atzeni F, Caporali R, Bobbio-Pallavicini F, Favalli EG. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. *Ann N Y Acad Sci*. 2009 Sep;1173:837-46. PubMed PMID: 19758236.

Defendenti C, Spina MF, Castiglione A, Atzeni F, Miadonna A, Saudelli M, Guercilena G, **Sarzi-Puttini P**. [Alveolar hemorrhage in pulmonary-renal syndrome anti-SCL/70 and anti-MPO-ANCA positive]. *Recenti Prog Med*. 2009 Jul-Aug;100(7-8):361-4. Italian. PubMed PMID: 19725477.

Salaffi F, **Sarzi-Puttini P**, Girolimetti R, Gasparini S, Atzeni F, Grassi W. Development and validation of the self-administered Fibromyalgia Assessment Status: a disease-specific composite measure for evaluating treatment effect. *Arthritis Res Ther*. 2009;11(4):R125. Epub 2009 Aug 18. PubMed PMID: 19686606; PubMed Central PMCID: PMC2745809.

Atzeni F, **Sarzi-Puttini P**, Vena GA. Resistant cases of psoriatic arthritis: how to manage them. *J Rheumatol Suppl*. 2009 Aug;83:73-5. PubMed PMID: 19661549.

Pallavicini FB, Caporali R, **Sarzi-Puttini P**, Atzeni F, Bazzani C, Gorla R, Marchesoni A, Favalli EG, Montecucco C. Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. *Autoimmun Rev*. 2010 Jan;9(3):175-80. Epub 2009 Jul 30. PubMed PMID: 19647103.

Casale R, **Sarzi-Puttini P**, Atzeni F, Gazzoni M, Buskila D, Rainoldi A. Central motor control failure in fibromyalgia: a surface electromyography study. *BMC Musculoskelet Disord*. 2009 Jul 1;10:78. PubMed PMID: 19570214; PubMed Central PMCID: PMC2714295.

Filippini M, Bazzani C, Favalli EG, Marchesoni A, Atzeni F, **Sarzi-Puttini P**, Pallavicini FB, Caporali R, Gorla R. Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. *Clin Rev Allergy Immunol*. 2010 Apr;38(2-3):90-6. PubMed PMID: 19548124.

Atzeni F, Ardizzone S, Bertani L, Antivalle M, Batticciotto A, **Sarzi-Puttini P**. Combined therapeutic approach: inflammatory bowel diseases and peripheral or axial arthritis. *World J Gastroenterol*. 2009 May 28;15(20):2469-71. PubMed PMID: 19468996; PubMed Central PMCID: PMC2686904.

Turiel M, Atzeni F, Tomasoni L, de Portu S, Delfino L, Bodini BD, Longhi M, Sitia S, Bianchi M, Ferrario P, Doria A, De Gennaro Colonna V, **Sarzi-Puttini P**. Non-invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients. *Rheumatology (Oxford)*. 2009 Jul;48(7):834-9. Epub 2009 May 22. PubMed PMID: 19465588.

Atzeni F, Antivalle M, Pallavicini FB, Caporali R, Bazzani C, Gorla R, Favalli EG, Marchesoni A, **Sarzi-Puttini P**. Predicting response to anti-TNF treatment in rheumatoid arthritis patients. *Autoimmun Rev*. 2009 Mar;8(5):431-7. Epub 2009 Jan 27. PubMed PMID: 19211043.

Bazzani C, Filippini M, Caporali R, Bobbio-Pallavicini F, Favalli EG, Marchesoni A, Atzeni F, **Sarzi-Puttini P**, Gorla R. Anti-TNFalpha therapy in a cohort of rheumatoid arthritis patients: clinical outcomes. *Autoimmun Rev*. 2009 Jan;8(3):260-5. Epub 2008 Nov 21. PubMed PMID: 19027090.

Favalli EG, Desiati F, Atzeni F, **Sarzi-Puttini P**, Caporali R, Pallavicini FB, Gorla R, Filippini M, Marchesoni A. Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. *Autoimmun Rev*. 2009 Jan;8(3):266-73. Epub 2008 Nov 18. PubMed PMID: 19022409.

Caporali R, Pallavicini FB, Filippini M, Gorla R, Marchesoni A, Favalli EG, **Sarzi-Puttini P**, Atzeni F, Montecucco C. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. *Autoimmun Rev*. 2009 Jan;8(3):274-80. Epub 2008 Nov 17. Review. PubMed PMID: 19017546.

Sitia S, Atzeni F, **Sarzi-Puttini P**, Di Bello V, Tomasoni L, Delfino L, Antonini-Canterin F, Di Salvo G, De Gennaro Colonna V, La Carrubba S, Carerj S, Turiel M. Cardiovascular involvement in systemic autoimmune diseases. *Autoimmun Rev*. 2009 Feb;8(4):281-6. Epub 2008 Sep 24. Review. PubMed PMID: 18817899.

- Doria A, Zampieri S, **Sarzi-Puttini P**. Exploring the complex relationships between infections and autoimmunity. *Autoimmun Rev*. 2008 Dec;8(2):89-91. Epub 2008 Aug 24. PubMed PMID: 18725325.
- Doria A, **Sarzi-Puttini P**, Shoenfeld Y. Infections, rheumatism and autoimmunity: the conflicting relationship between humans and their environment. *Autoimmun Rev*. 2008 Oct;8(1):1-4. Epub 2008 Aug 14. Review. PubMed PMID: 18707029.
- Buskila D, Atzeni F, **Sarzi-Puttini P**. Etiology of fibromyalgia: the possible role of infection and vaccination. *Autoimmun Rev*. 2008 Oct;8(1):41-3. Epub 2008 Aug 13. Review. PubMed PMID: 18706528.
- Mattia C, Coluzzi F, **Sarzi Puttini P**, Viganó R. Paracetamol/Tramadol association: the easy solution for mild-moderate pain. *Minerva Med*. 2008 Aug;99(4):369-90. Review. PubMed PMID: 18663345.
- Le Loët X, Nordström D, Rodriguez M, Rubbert A, **Sarzi-Puttini P**, Wouters JM, Woolley JM, Wright N, Lawrence C, Appleton B. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial. *J Rheumatol*. 2008 Aug;35(8):1538-44. Epub 2008 Jul 15. PubMed PMID: 18634163.
- Ardizzone S, **Puttini PS**, Cassinotti A, Porro GB. Extraintestinal manifestations of inflammatory bowel disease. *Dig Liver Dis*. 2008 Jul;40 Suppl 2:S253-9. Review. PubMed PMID: 18598997.
- Baio P, Brucato A, Buskila D, Gershwin ME, Giacomazzi D, Lopez LR, Luzzati R, Matsuura E, Selmi C, **Sarzi-Puttini P**, Atzeni F. Autoimmune diseases and infections: controversial issues. *Clin Exp Rheumatol*. 2008 Jan-Feb;26(1 Suppl 48):S74-80. Review. PubMed PMID: 18570758.
- Atzeni F, Bendtzen K, Bobbio-Pallavicini F, Conti F, Cutolo M, Montecucco C, Sulli A, Valesini G, **Sarzi-Puttini P**. Infections and treatment of patients with rheumatic diseases. *Clin Exp Rheumatol*. 2008 Jan-Feb;26(1 Suppl 48):S67-73. Review. PubMed PMID: 18570757.
- Croce F, Piconi S, Atzeni F, **Sarzi-Puttini P**, Galli M, Clerici M. HIV/AIDS: epidemic update, new treatment strategies and impact on autoimmunity. *Clin Exp Rheumatol*. 2008 Jan-Feb;26(1 Suppl 48):S48-52. Review. PubMed PMID: 18570754.
- Antonelli A, Ferri C, Galeazzi M, Giannitti C, Manno D, Mieli-Vergani G, Menegatti E, Olivieri I, Puoti M, Palazzi C, Roccatello D, Vergani D, **Sarzi-Puttini P**, Atzeni F. HCV infection: pathogenesis, clinical manifestations and therapy. *Clin Exp Rheumatol*. 2008 Jan-Feb;26(1 Suppl 48):S39-47. Review. PubMed PMID: 18570753.
- Gatta A, Giannini C, Lampertico P, Pontisso P, Quarta S, Zignego AL, Atzeni F, **Sarzi-Puttini P**. Hepatotropic viruses: new insights in pathogenesis and treatment. *Clin Exp Rheumatol*. 2008 Jan-Feb;26(1 Suppl 48):S33-8. Review. PubMed PMID: 18570752.
- Amital H, Govoni M, Maya R, Meroni PL, Ori B, Shoenfeld Y, Tincani A, Trotta F, **Sarzi-Puttini P**, Atzeni F. Role of infectious agents in systemic rheumatic diseases. *Clin Exp Rheumatol*. 2008 Jan-Feb;26(1 Suppl 48):S27-32. Review. PubMed PMID: 18570751.
- Atzeni F, **Sarzi-Puttini P**, Lama N, Bonacci E, Bobbio-Pallavicini F, Montecucco C, Caporali R. Anti-cyclic citrullinated peptide antibodies in primary Sjögren syndrome may be associated with non-erosive synovitis. *Arthritis Res Ther*. 2008;10(3):R51. Epub 2008 May 7. PubMed PMID: 18462485; PubMed Central PMCID: PMC2483440.
- Straub RH, Pongratz G, Cutolo M, Wijbrandts CA, Baeten D, Fleck M, Atzeni F, Grunke M, Kalden JR, Schölmerich J, Lorenz HM, Tak PP, **Sarzi-Puttini P**. Increased cortisol relative to adrenocorticotrophic hormone predicts improvement during anti-tumor necrosis factor therapy in rheumatoid arthritis. *Arthritis Rheum*. 2008 Apr;58(4):976-84. PubMed PMID: 18383357. **(Q1; IF 9.00)**
- Atzeni F, **Sarzi-Puttini P**, DePortu S, Cutolo M, Carrabba M, Straub RH. In etanercept-treated psoriatic arthritis patients clinical improvement correlated with an increase of serum cortisol relative to other adrenal hormones. *Clin Exp Rheumatol*. 2008 Jan-Feb;26(1):103-8. PubMed PMID: 18328154.
- Atzeni F, **Sarzi-Puttini P**. Autoantibody production in patients treated with anti-TNF-alpha. *Expert Rev Clin Immunol*. 2008 Mar;4(2):275-80. PubMed PMID: 20477056.
- Pace F, Scarlata P, Casini V, **Sarzi-Puttini P**, Porro GB. Validation of the reflux disease questionnaire for an Italian population of patients with gastroesophageal reflux disease. *Eur J Gastroenterol Hepatol*. 2008 Mar;20(3):187-90. PubMed PMID: 18301298. **(IF 2,35)**
- Buskila D, **Sarzi-Puttini P**. Fibromyalgia and autoimmune diseases: the pain behind autoimmunity. *Isr Med Assoc J*. 2008 Jan;10(1):77-8. Review. PubMed PMID: 18300581. **(Q3; IF 0.85)**
- Asherson RA, Cervera R, Klumb E, Stojanovic L, **Sarzi-Puttini P**, Yin H, Bucciarelli S, Espinosa G, Levy R, Shoenfeld Y. Amputation of digits or limbs in patients with antiphospholipid syndrome. *Semin Arthritis Rheum*. 2008 Oct;38(2):124-31. Epub 2008 Feb 21. PubMed PMID: 18206213. **(Q1; IF 4.75)**
- Doria A, Arienti S, Rampudda M, Canova M, Tonon M, **Sarzi-Puttini P**. Preventive strategies in systemic lupus erythematosus. *Autoimmun Rev*. 2008 Jan;7(3):192-7. Epub 2007 Dec 3. Review. PubMed PMID: 18190877.
- Atzeni F, Doria A, Ghirardello A, Turiel M, Batticciotto A, Carrabba M, **Sarzi-Puttini P**. Anti-thyroid antibodies and thyroid dysfunction in rheumatoid arthritis: prevalence and clinical value. *Autoimmunity*. 2008 Feb;41(1):111-5. PubMed PMID: 18176873. **(Q2; IF 2.71)**
- Atzeni F, Doria A, Ghirardello A, Villalta D, Zampieri S, Carrabba M, **Sarzi-Puttini P**. Organ-specific autoantibodies in patients with rheumatoid arthritis treated with adalimumab: a prospective long-term follow-up. *Autoimmunity*. 2008 Feb;41(1):87-91. PubMed PMID: 18176869. **(Q2; IF 2.71)**

Sarzi-Puttini P, Atzeni F, Di Franco M, Lama N, Batticciotto A, Iannuccelli C, Dell'Acqua D, de Portu S, Ricciari V, Carrabba M, Buskila D, Doria A, Valesini G. Anti-polymer antibodies are correlated with pain and fatigue severity in patients with fibromyalgia syndrome. *Autoimmunity*. 2008 Feb;41(1):74-9. PubMed PMID: 18176867. **(Q2; IF 2.71)**

Sarzi-Puttini P, Doria A. Organ specific-autoantibodies: their role as markers and predictors of disease. *Autoimmunity*. 2008 Feb;41(1):1-10. Review. PubMed PMID: 18176859. **(Q2; IF 2.71)**

Sarzi-Puttini P, Buskila D, Carrabba M, Doria A, Atzeni F. Treatment strategy in fibromyalgia syndrome: where are we now? *Semin Arthritis Rheum*. 2008 Jun;37(6):353-65. Epub 2007 Oct 31. Review. PubMed PMID: 17976693. **(Q1; IF 4.75)**

Turiel M, Sitia S, Atzeni F, **Sarzi-Puttini P**. Diagnosis of cardiac involvement in systemic autoimmune diseases. *Expert Rev Clin Immunol*. 2007 Nov;3(6):839-43. PubMed PMID: 20477131. **(Q2; IF 3.90)**

Bassi N, Ghirardello A, Iaccarino L, Zampieri S, Rampudda ME, Atzeni F, **Sarzi-Puttini P**, Shoenfeld Y, Doria A. OxLDL/beta2GPI-anti-oxLDL/beta2GPI complex and atherosclerosis in SLE patients. *Autoimmun Rev*. 2007 Nov;7(1):52-8. Epub 2007 Jul 24. Review. PubMed PMID: 17967726. **(Q1, IF 7.71)**

Iaccarino L, Arienti S, Rampudda M, Canova M, Atzeni F, **Sarzi-Puttini P**, Doria A. Mycophenolate mofetil in lupus glomerulonephritis: effectiveness and tolerability. *Ann N Y Acad Sci*. 2007 Sep;1110:516-24. PubMed PMID: 17911467. **(Q1; IF 4.76)**

Atzeni F, **Sarzi-Puttini P**, De Blasio G, Delfino L, Tomasoni L, Turiel M. Preclinical impairment of coronary flow reserve in patients with rheumatoid arthritis. *Ann N Y Acad Sci*. 2007 Jun;1108:392-7. PubMed PMID: 17894002. **(Q1; IF 4.76)**

Atzeni F, Boiardi L, Casali B, Farnetti E, **Sarzi-Puttini P**, Pipitone N, Olivieri I, Cantini F, Salvi F, La Corte R, Triolo G, Filippini D, Paolazzi G, Salvarani C. Lack of association of the -463 G/A myeloperoxidase promoter polymorphism with Behcet's disease in Italian patients. *Rheumatology (Oxford)*. 2007 Oct;46(10):1547-50. Epub 2007 Sep 12. PubMed PMID: 17855424.

Atzeni F, Doria A, Turiel M, **Sarzi-Puttini P**. What is the role of rituximab in the treatment of rheumatoid arthritis? *Autoimmun Rev*. 2007 Sep;6(8):553-8. Review. Erratum in: *Autoimmun Rev*. 2010 Sep;9(11):793. PubMed PMID: 17854748. **(Q1, IF 7.71)**

Carville SF, Arendt-Nielsen S, Bliddal H, Blotman F, Branco JC, Buskila D, Da Silva JA, Danneskiold-Samsøe B, Dincer F, Henriksson C, Henriksson KG, Kosek E, Longley K, McCarthy GM, Perrot S, Puszczewicz M, **Sarzi-Puttini P**, Silman A, Späth M, Choy EH; EULAR. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. *Ann Rheum Dis*. 2008 Apr;67(4):536-41. Epub 2007 Jul 20. Review. PubMed PMID: 17644548. **(Q1; IF 16.02)**

Iaccarino L, Rampudda M, Canova M, Della Libera S, **Sarzi-Puttini P**, Doria A. Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases? *Autoimmun Rev*. 2007 Jan;6(3):190-5. Epub 2006 Dec 1. Review. PubMed PMID: 17289556. **(Q1, IF 7.71)**

Buskila D, **Sarzi-Puttini P**, Ablin JN. The genetics of fibromyalgia syndrome. *Pharmacogenomics*. 2007 Jan;8(1):67-74. Review. PubMed PMID: 17187510. **(Q2; IF 4.22)**

Bordin G, Atzeni F, Bettazzi L, Beyene NB, Carrabba M, **Sarzi-Puttini P**. Unilateral polymyalgia rheumatica with contralateral sympathetic dystrophy syndrome. A case of asymmetrical involvement due to pre-existing peripheral palsy. *Rheumatology (Oxford)*. 2006 Dec;45(12):1578-80. PubMed PMID: 17085469. **(Q1, IF 5.60)**

Doria A, Iaccarino L, Ghirardello A, Zampieri S, Arienti S, **Sarzi-Puttini P**, Atzeni F, Piccoli A, Todesco S. Long-term prognosis and causes of death in systemic lupus erythematosus. *Am J Med*. 2006 Aug;119(8):700-6. PubMed PMID: 16887417. **(Q1; IF 4.76)**

Buskila D, **Sarzi-Puttini P**. Biology and therapy of fibromyalgia. Genetic aspects of fibromyalgia syndrome. *Arthritis Res Ther*. 2006;8(5):218. Review. PubMed PMID: 16887010; PubMed Central PMCID: PMC1779444. **(Q1, IF 4.10)**

Doria A, Iaccarino L, **Sarzi-Puttini P**, Ghirardello A, Zampieri S, Arienti S, Cutolo M, Todesco S. Estrogens in pregnancy and systemic lupus erythematosus. *Ann N Y Acad Sci*. 2006 Jun;1069:247-56. Review. PubMed PMID: 16855151. **(Q1; IF 4.76)**

Sarzi-Puttini P, Atzeni F, Diana A, Doria A, Furlan R. Increased neural sympathetic activation in fibromyalgia syndrome. *Ann N Y Acad Sci*. 2006 Jun;1069:109-17. Review. PubMed PMID: 16855138. **(Q1; IF 4.76)**

Straub RH, Härle P, **Sarzi-Puttini P**, Cutolo M. Tumor necrosis factor-neutralizing therapies improve altered hormone axes: an alternative mode of antiinflammatory action. *Arthritis Rheum*. 2006 Jul;54(7):2039-46. Review. PubMed PMID: 16802339. **(Q1; IF 9.00)**

Härle P, **Sarzi-Puttini P**, Cutolo M, Straub RH. No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2006 Jul;65(7):970-1. PubMed PMID: 16769786; PubMed Central PMCID: PMC1798194. **(Q1; IF 16.02)**

Ghirardello A, Zampieri S, Tarricone E, Iaccarino L, Bendo R, Briani C, Rondinone R, **Sarzi-Puttini P**, Todesco S, Doria A. Clinical implications of autoantibody screening in patients with autoimmune myositis. *Autoimmunity*. 2006 May;39(3):217-21. PubMed PMID: 16769655. **(Q2; IF 2.91)**

Zampieri S, Ghirardello A, Iaccarino L, Briani C, **Sarzi-Puttini P**, Atzeni F, Arienti S, Todesco S, Doria A. Polymyositis-dermatomyositis and infections. *Autoimmunity*. 2006 May;39(3):191-6. Review. PubMed PMID: 16769652. **(Q2; IF 2.91)**

Briani C, Doria A, **Sarzi-Puttini P**, Dalakas MC. Update on idiopathic inflammatory myopathies. *Autoimmunity*. 2006 May;39(3):161-70. Review. PubMed PMID: 16769649. **(Q2; IF 2.91)**

Rinaldi S, Ghisi M, Iaccarino L, Zampieri S, Ghirardello A, **Sarzi-Puttini P**, Ronconi L, Perini G, Todesco S, Sanavio E, Doria A. Influence of coping skills on health-related quality of life in patients with systemic lupus erythematosus. *Arthritis Rheum*. 2006 Jun 15;55(3):427-33. PubMed PMID: 16739209. **(Q1; IF 9.00)**

Atzeni F, **Sarzi-Puttini P**, Bevilacqua M. Calcium deposition and associated chronic diseases (atherosclerosis, diffuse idiopathic skeletal hyperostosis, and others). *Rheum Dis Clin North Am*. 2006 May;32(2):413-26, viii. Review. PubMed PMID: 16716887. **(Q1; IF 3.24)**

Sarzi-Puttini P, Atzeni F. Pyogenic arthritis of the facet joints: a growing problem for patients, a growing concern for clinicians. *Semin Arthritis Rheum*. 2006 Apr;35(5):269-70. PubMed PMID: 16616148. **(Q1; IF 4.75)**

Atzeni F, Carrabba M, Davin JC, Francès C, Ferri C, Guillemin L, Jorizzo JL, Mascia MT, Patel MJ, Pagnoux C, Vulpio L, **Sarzi-Puttini P**. Skin manifestations in vasculitis and erythema nodosum. *Clin Exp Rheumatol*. 2006 Jan-Feb;24(1 Suppl 40):S60-6. PubMed PMID: 16466626. **(Q2; IF 3.31)**

Albrecht J, Atzeni F, Baldini C, Bombardieri S, Dalakas MC, Demirkesen C, Yazici H, Mat C, Werth VP, **Sarzi-Puttini P**. Skin involvement and outcome measures in systemic autoimmune diseases. *Clin Exp Rheumatol*. 2006 Jan-Feb;24(1 Suppl 40):S52-9. Review. PubMed PMID: 16466625. **(Q2; IF 3.31)**

Atzeni F, Bardoni A, Cutolo M, Hunzelmann N, Krieg T, Martini G, Montecucco C, Olski TM, Secchi ME, Valentini G, Zulian F, **Sarzi-Puttini P**. Localized and systemic forms of scleroderma in adults and children. *Clin Exp Rheumatol*. 2006 Jan-Feb;24(1 Suppl 40):S36-45. Review. PubMed PMID: 16466623. **(Q2; IF 3.31)**

Marchesoni A, **Sarzi Puttini P**, Gorla R, Caporali R, Arnoldi C, Atzeni F, Vianelli M, Pallavicini FB. Cyclosporine in addition to infliximab and methotrexate in refractory rheumatoid arthritis. *Clin Exp Rheumatol*. 2005 Nov-Dec;23(6):916-7. PubMed PMID: 16396721. **(Q2; IF 3.31)**

Briani C, Zara G, Rondinone R, Iaccarino L, Ruggero S, Toffanin E, Ermani M, Ghirardello A, Zampieri S, **Sarzi-Puttini P**, Doria A. Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus. *Autoimmunity*. 2005 Nov;38(7):549-55. PubMed PMID: 16373260. **(Q2; IF 2.91)**

Sarzi-Puttini P, Atzeni F, Iaccarino L, Doria A. Environment and systemic lupus erythematosus: an overview. *Autoimmunity*. 2005 Nov;38(7):465-72. Review. PubMed PMID: 16373251. **(Q2; IF 2.91)**

Atzeni F, **Sarzi-Puttini P**, Dell'Acqua D, de Portu S, Cecchini G, Cruini C, Carrabba M, Meroni PL. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. *Arthritis Res Ther*. 2006;8(1):R3. PubMed PMID: 16356192; PubMed Central PMCID: PMC1526573. **(Q1, IF 4.10)**

Doria A, **Sarzi-Puttini P**, Shoenfeld Y. 2nd conference on heart, rheumatism and autoimmunity, Pescara, Italy, May 19-20, 2005. *Autoimmun Rev*. 2006 Jan;5(1):55-63. Epub 2005 Aug 10. PubMed PMID: 16338212. **(Q1, IF 7.71)**

Sarzi-Puttini P, Atzeni F, Doria A, Iaccarino L, Turiel M. Tumor necrosis factor-alpha, biologic agents and cardiovascular risk. *Lupus*. 2005;14(9):780-4. Review. PubMed PMID: 16218487. **(Q1, IF 2.6)**

Turiel M, Peretti R, **Sarzi-Puttini P**, Atzeni F, Doria A. Cardiac imaging techniques in systemic autoimmune diseases. *Lupus*. 2005;14(9):727-31. Review. PubMed PMID: 16218476. **(Q1, IF 2.6)**

Atzeni F, **Sarzi-Puttini P**, Doria A, Boiardi L, Pipitone N, Salvarani C. Behçet's disease and cardiovascular involvement. *Lupus*. 2005;14(9):723-6. Review. PubMed PMID: 16218475. **(Q1, IF 2.6)**

Doria A, Iaccarino L, **Sarzi-Puttini P**, Atzeni F, Turriel M, Petri M. Cardiac involvement in systemic lupus erythematosus. *Lupus*. 2005;14(9):683-6. Review. PubMed PMID: 16218467. **(Q1, IF 2.6)**

Doria A, **Sarzi-Puttini P**. Heart, rheumatism and autoimmunity: an old intriguing link. *Lupus*. 2005;14(9):643-5. PubMed PMID: 16218458. **(Q1, IF 2.6)**

Capsoni F, **Sarzi-Puttini P**, Zanella A. Primary and secondary autoimmune neutropenia. *Arthritis Res Ther*. 2005;7(5):208-14. Epub 2005 Aug 31. Review. PubMed PMID: 16207350; PubMed Central PMCID: PMC1257445. **(Q1, IF 4.10)**

Carrabba M, **Sarzi-Puttini P**. Introduction: osteoarthritis in the third millennium: a new era for an old disease? *Semin Arthritis Rheum*. 2005 Jun;34(6 Suppl 2):1-2. Review. PubMed PMID: 16206946. **(Q1; IF 4.75)**

Atzeni F, **Sarzi-Puttini P**, Capsoni F, Mecchia M, Marrazza MG, Carrabba M. Successful treatment of resistant Behçet's disease with etanercept. *Clin Exp Rheumatol*. 2005 Sep-Oct;23(5):729. PubMed PMID: 16173263. **(Q1, IF 3.01)**

Furlan R, Colombo S, Perego F, Atzeni F, Diana A, Barbic F, Porta A, Pace F, Malliani A, **Sarzi-Puttini P**. Abnormalities of cardiovascular neural control and reduced orthostatic tolerance in patients with primary fibromyalgia. *J Rheumatol*. 2005 Sep;32(9):1787-93. PubMed PMID: 16142879. **(Q1; IF 3.18)**

Atzeni F, Ardizzone S, **Sarzi-Puttini P**, Colombo E, Maconi G, De Portu S, Carrabba M, Bianchi Porro G. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study. *Aliment Pharmacol Ther*. 2005 Sep 1;22(5):453-61. PubMed PMID: 16128684. **(Q1; IF 7.35)**

Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, **Sarzi-Puttini P**. Autoimmunity and anti-TNF-alpha agents. *Ann N Y Acad Sci*. 2005 Jun;1051:559-69. Review. PubMed PMID: 16126996. **(Q1; IF 4.76)**

Zampieri S, Iaccarino L, Ghirardello A, Tarricone E, Arienti S, **Sarzi-Puttini P**, Gambari P, Doria A. Systemic lupus erythematosus, atherosclerosis, and autoantibodies. *Ann N Y Acad Sci*. 2005 Jun;1051:351-61. Review. PubMed PMID: 16126977. **(Q1; IF 4.76)**

Turiel M, **Sarzi-Puttini P**, Peretti R, Bonizzato S, Muzzupappa S, Atzeni F, Rossi E, Doria A. Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. *Am J Cardiol*. 2005 Aug 15;96(4):574-9. PubMed PMID: 16098314. **(Q1; IF 2.57)**

Zampieri S, Alaibac M, Iaccarino L, Rondinone R, Ghirardello A, **Sarzi-Puttini P**, Peserico A, Doria A. Tumour necrosis factor alpha is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus. *Ann Rheum Dis*. 2006 Apr;65(4):545-8. Epub 2005 Aug 11. PubMed PMID: 16096331; PubMed Central PMCID: PMC1798098. (**Q1**; **IF 16.02**)

Sarzi-Puttini P, Cimmino MA, Scarpa R, Caporali R, Parazzini F, Zaninelli A, Atzeni F, Marcolongo R. Do physicians treat symptomatic osteoarthritis patients properly? Results of the AMICA experience. *Semin Arthritis Rheum*. 2005 Aug;35(1 Suppl 1):38-42. PubMed PMID: 16084232. (**Q1**; **IF 4.75**)

Caporali R, Cimmino MA, **Sarzi-Puttini P**, Scarpa R, Parazzini F, Zaninelli A, Ciocci A, Montecucco C. Comorbid conditions in the AMICA study patients: effects on the quality of life and drug prescriptions by general practitioners and specialists. *Semin Arthritis Rheum*. 2005 Aug;35(1 Suppl 1):31-7. PubMed PMID:16084231. (**Q1**; **IF 4.75**)

Scarpa R, **Sarzi-Puttini P**, Cimmino MA, Caporali R, Parazzini F, Zaninelli A, Canesi B. Analysis of pharmacologic and nonpharmacologic prescription patterns of general practitioners and specialists in the AMICA study. *Semin Arthritis Rheum*. 2005 Aug;35(1 Suppl 1):24-30. PubMed PMID: 16084230. (**Q1**; **IF 4.75**)

Cimmino MA, **Sarzi-Puttini P**, Scarpa R, Caporali R, Parazzini F, Zaninelli A, Marcolongo R. Clinical presentation of osteoarthritis in general practice: determinants of pain in Italian patients in the AMICA study. *Semin Arthritis Rheum*. 2005 Aug;35(1 Suppl 1):17-23. PubMed PMID: 16084229. (**Q1**; **IF 4.75**)

Parazzini F, Cimmino MA, **Sarzi-Puttini P**, Scarpa R, Caporali R, Zaninelli A, Ciocci A. The characteristics of symptomatic osteoarthritis in general and specialist practice in Italy: design and methods of the AMICA Study. *Semin Arthritis Rheum*. 2005 Aug;35(1 Suppl 1):11-6. PubMed PMID: 16084228. (**Q1**; **IF 4.75**)

Sarzi-Puttini P, Cimmino MA, Scarpa R, Caporali R, Parazzini F, Zaninelli A, Atzeni F, Canesi B. Osteoarthritis: an overview of the disease and its treatment strategies. *Semin Arthritis Rheum*. 2005 Aug;35(1 Suppl 1):1-10. Review. PubMed PMID: 16084227. (**Q1**; **IF 4.75**)

Sarzi-Puttini P, Atzeni F, Schölmerich J, Cutolo M, Straub RH. Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3. *Ann Rheum Dis*. 2006 Mar;65(3):301-5. Epub 2005 Aug 3. PubMed PMID: 16079165; PubMed Central PMCID: PMC1798065. (**Q1**; **IF 16.02**)

Straub RH, Härle P, Atzeni F, Weidler C, Cutolo M, **Sarzi-Puttini P**. Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy. *J Rheumatol*. 2005 Jul;32(7):1253-8. PubMed PMID: 15996060 (**Q1**; **IF 3.18**)

Turiel M, **Sarzi-Puttini P**, Peretti R, Rossi E, Atzeni F, Parsons W, Doria A. Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study. *Stroke*. 2005 Jul;36(7):1490-4. Epub 2005 Jun 9. PubMed PMID: 15947270. (**Q1**; **IF 6.03**)

Härle P, Straub RH, Wiest R, Mayer A, Schölmerich J, Atzeni F, Carrabba M, Cutolo M, **Sarzi-Puttini P**. Increase of sympathetic outflow measured by neuropeptide Y and decrease of the hypothalamic-pituitary-adrenal axis tone in patients with systemic lupus erythematosus and rheumatoid arthritis: another example of uncoupling of response systems. *Ann Rheum Dis*. 2006 Jan;65(1):51-6. Epub 2005 Jun 7. PubMed PMID: 15941834; PubMed Central PMCID: PMC1797997. (**Q1**; **IF 16.02**)

Turiel M, Peretti R, Mornati D, Delfino L, Atzeni F, **Sarzi-Puttini P**. The role of echocardiographic techniques in connective tissue diseases. *Autoimmun Rev*. 2005 Mar;4(3):171-7. Review. PubMed PMID: 15823503. (**Q1**, **IF 7.61**)

Sarzi-Puttini P, Atzeni F, Shoenfeld Y, Ferraccioli G. TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. *Autoimmun Rev*. 2005 Mar;4(3):153-61. Review. PubMed PMID: 15823501. (**Q1**, **IF 7.61**)

Atzeni F, **Sarzi-Puttini P**, Doria A, Iaccarino L, Capsoni F. Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review. *Autoimmun Rev*. 2005 Mar;4(3):144-52. Review. PubMed PMID: 15823500. (**Q1**, **IF 7.61**)

Capsoni F, Minonzio F, **Sarzi-Puttini P**, Atzeni F, Ambrosi B. Thyroid acropachy: an unusual rheumatic manifestation of Graves' disease. *Clin Exp Rheumatol*. 2005 Jan-Feb;23(1):125-6. PubMed PMID: 15789906. (**Q1**, **IF 3.01**)

Lubrano E, **Sarzi Puttini P**, Parsons WJ, D'Angelo S, Cimmino MA, Serino F, Pappone N. Validity and reliability of an Italian version of the revised Leeds disability questionnaire for patients with ankylosing spondylitis. *Rheumatology (Oxford)*. 2005 May;44(5):666-9. Epub 2005 Mar 9. PubMed PMID: 15757970. (**Q1**, **IF 5.60**)

Capsoni F, **Sarzi-Puttini P**, Atzeni F, Minonzio F, Bonara P, Doria A, Carrabba M. Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis. *Arthritis Res Ther*. 2005;7(2):R250-5. Epub 2005 Jan 10. PubMed PMID: 15743471; PubMed Central PMCID: PMC1065317. (**Q1**, **IF 4.10**)

Straub RH, **Sarzi-Puttini P**, Atzeni F, Buttgeit F, Carrabba M, Cutolo M. Anti-tumour necrosis factor antibody treatment does not change serum levels of cortisol binding globulin in patients with rheumatoid arthritis but it increases androstenedione relative to cortisol. *Ann Rheum Dis*. 2005 Sep;64(9):1353-6. Epub 2005 Feb 11. PubMed PMID: 15708882; PubMed Central PMCID: PMC1755630. (**Q1**; **IF 16.02**)

Pipitone N, Boiardi L, Olivieri I, Cantini F, Salvi F, Malatesta R, La Corte R, Triolo G, Ferrante A, Filippini D, Paolazzi G, Sarzi-Puttini P, Restuccia G, Salvarani C. Clinical manifestations of Behçet's disease in 137 Italian patients: results of a multicenter study. *Clin Exp Rheumatol*. 2004;22(6 Suppl 36):S46-51. PubMed PMID: 15675135. (**Q1**, **IF 3.01**)

Doria A, Ghirardello A, Iaccarino L, Zampieri S, Punzi L, Tarricone E, Ruffatti A, Sulli A, Sarzi-Puttini PC, Gambiari PF, Cutolo M. Pregnancy, cytokines, and disease activity in systemic lupus erythematosus. *Arthritis Rheum*. 2004 Dec 15;51(6):989-95. PubMed PMID: 15593367. (**Q1**; **IF 9.00**)

Meroni PL, Borghi MO, Raschi E, Ventura D, **Sarzi Puttini PC**, Atzeni F, Lonati L, Parati G, Tincani A, Mari D, Tedesco F. Inflammatory response and the endothelium. *Thromb Res*. 2004;114(5-6):329-34. Review. PubMed PMID: 15507262. (**Q2**; **IF 2.86**)

Rinaldi S, Doria A, Salaffi F, Ermani M, Iaccarino L, Ghirardello A, Zampieri S, **Sarzi-Puttini P**, Gambari PF, Perini G. Health-related quality of life in Italian patients with systemic lupus erythematosus. I. Relationship between physical and mental dimension and impact of age. *Rheumatology (Oxford)*. 2004 Dec;43(12):1574-9. Epub 2004 Sep 7. PubMed PMID: 15353611. **(Q1, IF 5.60)**

Salvarani C, Boiardi L, Casali B, Olivieri I, Cantini F, Salvi F, Malatesta R, La Corte R, Triolo G, Ferrante A, Filippini D, Paolazzi G, **Sarzi-Puttini P**, Nicoli D, Farnetti E, Chen Q, Pulsatelli L. Vascular endothelial growth factor gene polymorphisms in Behçet's disease. *J Rheumatol*. 2004 Sep;31(9):1785-9. PubMed PMID: 15338501. **(Q1; IF 3.18)**

Doria A, **Sarzi Puttini PC**, Shoenfeld Y. Heart, rheumatism and autoimmunity: Milan, Italy. February 5-7, 2004. *Autoimmun Rev*. 2004 Jun;3(4):337-54. PubMed PMID: 15246031.

Rizzi M, **Sarzi-Puttini P**, Atzeni F, Capsoni F, Andreoli A, Pecis M, Colombo S, Carrabba M, Sergi M. Cyclic alternating pattern: a new marker of sleep alteration in patients with fibromyalgia? *J Rheumatol*. 2004 Jun;31(6):1193-9. PubMed PMID: 15170935 **(Q1; IF 3.18)**

Atzeni F, Del Papa N, **Sarzi-Puttini P**, Bertolazzi F, Minonzio F, Capsoni F. CD69 expression on neutrophils from patients with rheumatoid arthritis. *Clin Exp Rheumatol*. 2004 May-Jun;22(3):331-4. PubMed PMID: 15144128.**(Q1, IF 3.01)**

Sarzi-Puttini P, Atzeni F. New developments in our understanding of DISH (diffuse idiopathic skeletal hyperostosis). *Curr Opin Rheumatol*. 2004 May;16(3):287-92. Review. PubMed PMID: 15103260. **(Q1; IF 4.00)**

Sarzi-Puttini P, Atzeni F, Turiel M, Furlan R, Vulpio L, Carrabba M, Pace F. The Italian version of the Fibrofatiigue Scale, a reliable tool for the evaluation of fibromyalgia symptoms. *J Psychosom Res*. 2004 Feb;56(2):213-6. PubMed PMID: 15016581.**(Q1; IF 2.86)**

Atzeni F, **Sarzi-Puttini P**, Capsoni F, Vulpio L, Carrabba M. Successful treatment of pure red cell aplasia in systemic lupus erythematosus with cyclosporin A. *Clin Exp Rheumatol*. 2003 Nov-Dec;21(6):759-62. Review. PubMed PMID: 14740456. **(Q1, IF 3.01)**

Sarzi-Puttini P, Ardizzone S, Manzionna G, Atzeni F, Colombo E, Antiville M, Carrabba M, Bianchi-Porro G. Infliximab-induced lupus in Crohn's disease: a case report. *Dig Liver Dis*. 2003 Nov;35(11):814-7. PubMed PMID: 14674674. **(Q2; IF 2.46)**

Pace F, Molteni P, Bollani S, **Sarzi-Puttini P**, Stockbrügger R, Bianchi Porro G, Drossman DA. Inflammatory bowel disease versus irritable bowel syndrome: a hospital-based, case-control study of disease impact on quality of life. *Scand J Gastroenterol*. 2003 Oct;38(10):1031-8. PubMed PMID: 14621276. **(Q2; IF 2.15)**

Sarzi-Puttini P, D'Ingianna E, Fumagalli M, Scarpellini M, Fiorini T, Chérié-Lignière EL, Panni B, Fiorentini F, Corbelli V, Beyene NB, Mastaglio C, Severi C, Locati M, Cazzola M, Menozzi G, Monti G, Saccardo F, Alfieri G, Atzeni F. An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis. *Rheumatol Int*. 2005 Jan;25(1):15-22. Epub 2003 Oct 7. PubMed PMID: 14530867. **(Q2, IF 2.2)**

Sarzi-Puttini P, Atzeni F, Fiorini T, Panni B, Randisi G, Turiel M, Carrabba M. Validation of an Italian version of the Fibromyalgia Impact Questionnaire (FIQ-I). *Clin Exp Rheumatol*. 2003 Jul-Aug;21(4):459-64. PubMed PMID: 12942697 **(Q1, IF 3.01)**

Pace F, **Sarzi Puttini P**, Manzionna G, Molteni P, Turiel M, Panni B, Bianchi-Porro G (2001). Visceral hypersensitivity is not a feature of fibromyalgia syndrome. *Journal Musculoskeletal pain* 2001; 9, 47-55, **(N/A)**

Turiel M, Gottardi B, Casiraghi S, Muzzupappa S, Buonamici V, **Sarzi-Puttini P**, Colombo A, Piccaluga E, Viecca M. Quantitative evaluation of regional left ventricular wall motion using color kinesis after percutaneous transluminal myocardial revascularization. *Am J Cardiol*. 2001 Apr 1;87(7):896-8. PubMed PMID: 11274948.. **(Q1; IF 2.57)**

Sarzi-Puttini P, Fiorini T, Panni B, Turiel M, Cazzola M, Atzeni F. Correlation of the score for subjective pain with physical disability, clinical and radiographic scores in recent onset rheumatoid arthritis. *BMC Musculoskelet Disord*. 2002 Jul 19;3:18. PubMed PMID: 12133169; PubMed Central PMCID: PMC117789. **(Q2; IF 2.05)**

Sarzi-Puttini P, Cazzola M, Panni B, Turiel M, Fiorini T, Belai-Beyene N, Chérié-Lignière EL. Long-term safety and efficacy of low-dose cyclosporin A in severe psoriatic arthritis. *Rheumatol Int*. 2002 Apr;21(6):234-8. PubMed PMID: 12036210. **(Q2, IF 2.2)**

Sarzi-Puttini P, Rizzi M, Andreoli A, Panni B, Pecis M, Colombo S, Turiel M, Carrabba M, Sergi M. Hypersomnolence in fibromyalgia syndrome. *Clin Exp Rheumatol*. 2002 Jan-Feb;20(1):69-72. PubMed PMID: 11892714. **(Q1, IF 3.01)**

Sarzi-Puttini P, Santandrea S, Boccassini L, Panni B, Caruso I. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. *Clin Exp Rheumatol*. 2001;19(1 Suppl 22):S17-20. PubMed PMID: 11296544**(Q1, IF 3.01)**

Cazzola M, Antiville M, **Sarzi-Puttini P**, Dell'Acqua D, Panni B, Caruso I. Oral type II collagen in the treatment of rheumatoid arthritis. A six-month double blind placebo-controlled study. *Clin Exp Rheumatol*. 2000 Sep-Oct;18(5):571-7. PubMed PMID: 11072596. **(Q1, IF 3.01)**

Sarzi-Puttini P, Panni B, Cazzola M, Muzzupappa S, Turiel M. Lamotrigine-induced lupus. *Lupus*. 2000;9(7):555-7. PubMed PMID: 11035425. **(Q2, IF 2.6)**

Turiel M, Muzzupappa S, Gottardi B, Crema C, **Sarzi-Puttini P**, Rossi E. Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography. *Lupus*. 2000;9(6):406-12. PubMed PMID: 10981643. **(Q2, IF 2.6)**

Sarzi-Puttini P, Comi D, Boccassini L, Muzzupappa S, Turiel M, Panni B, Salvaggio A. Diet therapy for rheumatoid arthritis. A controlled double-blind study of two different dietary regimens. *Scand J Rheumatol*. 2000;29(5):302-7. PubMed PMID: 11093596. **(Q2; IF 3.02)**

Sergi M, Rizzi M, Braghiroli A, **Sarzi Puttini P**, Greco M, Cazzola M, Andreoli A. Periodic breathing during sleep in patients affected by fibromyalgia syndrome. *Eur Respir J*. 1999 Jul;14(1):203-8. PubMed PMID: 10489852. **(Q1; IF 12,33)**

Caruso I, Santandrea S, **Sarzi Puttini P**, Montrone F, Boccassini L, Azzolini V, Cazzola M, Dell'Acqua D. Prevention of appearance of radiological lesions in early rheumatoid arthritis: a randomized, single-blind study comparing intra-articular rifamycin with auranofin. *J Int Med Res.* 1992 Feb;20(1):61-77. PubMed PMID: 1568521. **(Q3; IF 1.28)**

Caruso I, Santandrea S, **Sarzi Puttini P**, Boccassini L, Montrone F, Cazzola M, Azzolini V, Segre D. Clinical, laboratory and radiographic features in early rheumatoid arthritis. *J Rheumatol.* 1990 Oct;17(10):1263-7. PubMed PMID: 2254883. **(Q1; IF 3.18)**

Setti G, Calciolari CA, Cimino V, Zanini A, **Sarzi Puttini P**. The treatment of idiopathic and secondary hydrarthrosis of the knee by intra-articular Rifamycin SV. *Chir Organi Mov.* 1990 Oct-Dec;75(4):343-6. English, Italian. PubMed PMID: 2098221. **(N/A)**

Caruso I, **Sarzi Puttini P**, Cazzola M, Azzolini V. Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. *J Int Med Res.* 1990 May-Jun;18(3):201-9. PubMed PMID: 2193835. **(Q3; IF 1.28)**

Cazzola M, Caruso I, Montrone F, **Sarzi Puttini P**. Rheumatoid arthritis associated with osteopoikilosis: a case report. *Clin Exp Rheumatol.* 1989 Jul-Aug;7(4):423-6. PubMed PMID: 2556229. **(Q1, IF 3.01)**

Sarzi Puttini P, Cazzola M, Boccassini L, Ciniselli G, Santandrea S, Caruso I, Benvenuti C. A comparison of dothiepin versus placebo in the treatment of pain in rheumatoid arthritis and the association of pain with depression. *J Int Med Res.* 1988 Sep-Oct;16(5):331-7. PubMed PMID: 3058537. **(Q3; IF 1.28)**

Di Perri T, Auteri A, Caruso I, Corvetta A, Danieli G, **Sarzi-Puttini P**, Scaricabarozzi I. Multicenter double-blind randomized clinical trial of imidazole salicylate versus ibuprofen in patients with osteoarthritis. *Int J Clin Pharmacol Ther Toxicol.* 1987 Sep;25(9):479-82. PubMed PMID: 3316058. **(Q3)**

Caruso I, **Sarzi-Puttini P**, Boccassini L, Santandrea S, Locati M, Volpato R, Montrone F, Benvenuti C, Beretta A. Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome. *J Int Med Res.* 1987 May-Jun;15(3):154-9. PubMed PMID: 3301454.**(Q3; IF 1.28)**

Sarzi Puttini PC, Santandrea S, Boccassini L, Chemotti M, Saccardo F, Galli M. Absence of antinuclear antibodies in cryoprecipitates of patients with essential mixed or secondary non-lupoid cryoglobulinemia. *Ric Clin Lab.* 1986 Apr-Jun;16(2):341-4. PubMed PMID: 3491413. **(discontinued)**

Montrone F, Fumagalli M, **Sarzi Puttini P**, Boccassini L, Santandrea S, Volpato R, Locati M, Caruso I. Double-blind study of S-adenosyl-methionine versus placebo in hip and knee arthrosis. *Clin Rheumatol.* 1985 Dec;4(4):484-5. PubMed PMID: 3913558. **(Q2, IF 2,42)**

Caruso I, Fumagalli M, Boccassini L, **Sarzi Puttini P**, Ciniselli G, Cavallari G. Antidepressant activity of S-adenosylmethionine. *Lancet.* 1984 Apr 21;1(8382):904. PubMed PMID: 6143204. **(Q1, IF 60,392)**

Data

15 Dicembre 2020

Luogo

Milano